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Abstract
We designed a population-based cohort study to describe the characteristics and
outcomes of 6346 adults discharged home from an emergency department (ED) with
acute kidney injury (AKI). Within 30 days of discharge, 149 (2.3%) patients died (stage
1: 2.1%, stage 2: 5.2%, and stage 3 AKI: 15.9%). We also compared 30-day mortality to
patients hospitalized with AKI and patients discharged home with no AKI in two separate
propensity score-matched analyses. An ED discharge versus hospitalization was
associated with lower 30-day mortality (3.0% vs. 11.9%, relative risk (RR): 0.25, 95%
confidence interval (CI): 0.21-0.30). An ED discharge home with AKI versus no AKI
was associated with higher 30-day mortality (2.2% vs. 1.4%, RR: 1.56, 95% CI: 1.202.04). Although sicker patients are appropriately hospitalized, patients discharged home
from the ED with AKI remain at risk of adverse outcomes. A better understanding of care
appears warranted, as is testing strategies to improve care.
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Glossary of Terms
Acute kidney injury

a sudden deterioration in kidney function over a period of
hours to days, defined by relative changes in serum
creatinine concentration from baseline.

Admission

the need for patient care under a medical service in the
hospital setting.

Aggregated Diagnosis

a point score derived from the John Hopkins Adjusted

Group

Clinical Groups® system. It is a weighted measure of health
care utilization as a proxy measure for co-morbidity and
accounts for the duration of condition, severity of condition,
diagnostic certainty, etiology of the condition, and specialty
care involvement.

Albumin-to-creatinine

a ratio between urine albumin and urine creatinine. It is used

ratio

to diagnose and monitor kidney disease.

Angiotensin II receptor

a class of medication that blocks (inhibits) the binding of

blocker

angiotensin II to its receptor on smooth muscles surrounding
blood vessels. As a result, blood vessels enlarge or dilate,
and blood pressure is reduced. This medication also benefits
patients with heart and chronic kidney disease.

Angiotensin-converting

a class of medication that slows (inhibits) the activity of the

enzyme inhibitor

enzyme angiotensin-converting enzyme, which decreases
the production of angiotensin II. As a result, blood vessels
enlarge or dilate, and blood pressure is reduced. This
medication also benefits patients with heart and chronic
kidney disease.

Anti-retroviral

one of several classes of medications used to control an HIV
(a retrovirus) infection.

Anticoagulant

commonly referred to as blood thinners, a class of
medication that prevents or reduces the coagulation of
blood, prolonging the clotting time.

xiv

Antiplatelet

a class of medication that decreases the ability of a blood
clot to form by interfering with platelet activation (clumping
or aggregation).

Antipsychotic

also known as neuroleptics or major tranquilizers, a class of
medication used to manage psychosis (delusions,
hallucinations, paranoia or disordered thought), principally
in schizophrenia and bipolar disorder.

Abdominal aortic

an enlargement of the abdominal aorta (main artery of the

aneurysm

human body).

Atrial fibrillation or

atrial fibrillation is an abnormal heart rhythm characterized

flutter

by rapid and irregular beating by the top chambers (atria) of
the heart. Atrial flutter is characterized by a rapid, regular
beating by the atria.

Beta-adrenergic

commonly referred to as a beta-blocker, a class of

antagonist

medication that blocks the beta receptors of the adrenergic
sympathetic nervous system (flight or fight response), which
are located on a number of organs (e.g. kidneys, heart,
arteries). The net effect depends on the organ and type of
beta receptor. Effects include (but not limited to) the
reduction of heart rate and/or blood pressure.

Calcium channel

also known as calcium channel antagonist, a class of

blocker

medication that disrupts the movement of calcium.
Depending on the type of calcium channel blocker, the net
effect is a reduction of blood pressure by relaxing smooth
muscle in blood vessels or the slowing of the heart rate by
depressing the atrioventricular node in the heart.

Canadian Triage Acuity

a system that categorizes patients by both injury and

Scale

physiological findings, and ranks them by severity from 1–5
(1 being highest). The model is used by both paramedics
and Emergency Department nurses, and also for pre-arrival
notifications.

xv

Cerebrovascular disease

Vascular disease of the cerebral circulation involving
arteries supplying oxygen to the brain. A stroke is a
manifestation of cerebrovascular disease.

Charlson co-morbidity

also known as the Charlson score, an index that predicts the

index

one-year mortality for a patient who may have a range of
co-morbid conditions. The Charlson co-morbidity index is
based on the International Classification of Diseases
diagnosis codes found in administrative data.

Chronic kidney disease

the progressive loss in kidney function over a period of
months or years.

Chronic liver disease

progressive disease of the liver over a period of at least six
months.

Chronic obstructive

a progressive obstructive lung disease characterized by

pulmonary disease

long-term breathing problems and poor airflow. Symptoms
include shortness of breath, cough, and sputum production.

Coronary angiogram

a minimally invasive procedure to access the coronary
circulation and blood-filled chambers of the heart using a
catheter.

Coronary artery disease

disease in which a blockage (such as a waxy substance
called a plaque) develops inside the coronary arteries.
Coronary arteries supply oxygen-rich blood to the heart
muscle. An acute myocardial infarction (heart attack) is a
manifestation of coronary artery disease.

Coronary events

a term researchers and clinicians use to encompass a number
of important outcomes for patients with heart disease. These
outcomes may include myocardial infarction, ischemic heart
failure, unstable angina, sudden death, and procedures such
as a coronary angiogram or coronary artery bypass surgery.

Corticosteroid

a class of synthetic steroid hormone medication that reduces
inflammation and suppresses the immune system through a
variety of mechanisms.

xvi

Creatinine

a byproduct of muscle breakdown that appears in the blood,
is filtered by the kidneys, and excreted in the urine.

Dementia

a set of symptoms that are caused by disorders affecting the
brain. Symptoms include memory loss, difficulties with
thinking, problem-solving or language, which may be severe
enough to reduce a person's ability to perform everyday
activities.

Dialysis

the process of removing waste products and excess fluid
from the body through a machine. Dialysis is necessary
when the kidneys are not able to adequately filter toxins and
waste products from the blood.

Discharge

the release of a patient from a course of care, typically
referring to a patient who leaves hospital and goes home.

Disposition

the plan for continuing health care of a patient following
discharge or transfer from a given health care facility.

Diuretic

a class of medication that increases production of urine
(diuresis). Fluid (water and electrolytes) is excreted from the
body by the kidney, which may result in blood pressure
reduction. Certain diuretics promote the excretion of
potassium (non-potassium sparing) while others do not
(potassium-sparing).

Echocardiogram

an ultrasound of the heart.

Electronic health record

also known as an electronic medical record, a collection of
patient electronically-stored health information in a digital
format, which may supplement or replace a physical (paper)
form of the medical chart.

End-stage kidney

the final stage of chronic kidney disease in which the

disease

kidneys do not function well enough to meet the needs of
daily life. At this stage, renal replacement therapy is
required to sustain life.

xvii

Glomerular filtration

the sum of all filtration rates of all functioning nephrons in

rate

the kidney. This metric is used to assess kidney function in
routine care.

Heart failure

also known as congestive heart failure, heart failure occurs
when the heart is unable to pump sufficiently to maintain
blood flow to meet the body's needs.

Hypertension

elevated blood pressure.

Immunosuppressive

a class of medication that suppresses or reduces the strength

medication

of the body's immune system. Corticosteroids are also
considered immunosuppressive medications. However, they
have been separated into a class of their own in this study.

Kidney transplant

the process of when a transplanted kidney is rejected by the

rejection

person’s (recipient’s) immune system, destroying the
transplanted tissue.

Lower urinary tract

a group of clinical symptoms involving the bladder, urinary

symptoms

sphincter, urethra, and, in men, the prostate.

Myocardial infarction

also known as a heart attack, the blockage of blood flow to a
section of the heart. If blood flow is not restored quickly,
that section of the heart begins to die and the level of
damage depends on how long blood supply is cut off.

Nephrolithiasis

kidney stones.

Nephron

the basic structural and functional unit of the kidney. The
chief function of the nephron is to regulate the concentration
of water, soluble substances, and metabolic waste products
substances by filtering the blood, reabsorbing what is
needed, and excreting the rest as urine.

Non-steroidal anti-

a class of medication used to reduce pain, decrease fever,

inflammatory drug

and decrease inflammation. Non-steroidal anti-inflammatory
drugs work by inhibiting the activity of cyclooxygenase-1
and cyclooxygenase-2 (COX-2) enzymes, thereby inhibiting
the synthesis of prostaglandins and thromboxanes.

xviii

Oral hypoglycemic

also known as anti-hyperglycemic agents, a broad class of

agents

medications aimed to lower blood glucose levels.
Mechanism of action depends on the type of oral
hypoglycemic agent.

Osteoarthritis

a degenerative joint disease also known as “wear and tear”
arthritis. The cartilage or cushion between joints breaks
down leading to pain, stiffness and swelling.

Outpatient

a patient who receives medical treatment without being
admitted to a hospital.

Palliative care

a multidisciplinary approach to specialized medical and
nursing care for people with life-limiting illnesses, focusing
on providing people with relief from the symptoms, pain,
physical stress, and mental stress of the terminal diagnosis.

Parkinson’s disease

a progressive disorder of the nervous system that affects
movement.

Peripheral vascular

also known as peripheral arterial disease, the narrowing of

disease

the blood vessels other than those that supply the heart or
the brain.

Proton pump inhibitor

a class of medication that reduces gastric (stomach) acid
production. Proton pump inhibitors block the
hydrogen/potassium adenosine triphosphatase (ATP) pump
found in gastric cells.

Renal replacement

a therapy that replaces the normal blood-filtering function of

therapy

the kidneys. Renal replacement therapy is a broad term that
refers to all types of dialysis modalities as well as kidney
transplantation.

Revascularization

the restoration of perfusion to a body part or organ that has
suffered ischemia (reduction of blood supply resulting in the
shortage of oxygen in tissues). It is typically accomplished
by surgery. Vascular bypass and angioplasty are two
primary methods of revascularization.

xix

Rheumatoid arthritis

a long-term autoimmune disorder that primarily affects
joints. It typically results in warm, swollen, and painful
joints. In a person with an autoimmune disorder, their
immune system attacks their own body’s tissues.

Statin

a class of lipid-lowering (cholesterol) medications that
inhibit the HMG-CoA (3-hydroxy-3-methyl-glutarylcoenzyme A) reductase enzyme, which plays a central role
in the production of cholesterol.

Ultrasound

an imaging method that uses high-frequency sound waves to
produce images of structures within the body.

Uricosuric agents

a class of medication used to treat or prevent gout.
Uricosuric medications promote excretion of uric acid in the
urine.

Urine albumin

also known as albuminuria, the presence of albumin in the
urine. The amount of urine albumin is not expected to
exceed a threshold of 150 mg per day in patients with
normal kidney function. Albumin is a protein made by the
liver.

Urine dipstick

also known as a urine test strip, a basic diagnostic tool used
to determine if there are abnormal changes in a patient’s
urine. A standard urine dipstick may comprise of several
tests. Common tests include protein (albumin), glucose,
white blood cells, and hemoglobin (a component of red
blood cells).

Xanthine oxidase

a class of medication used to treat or prevent gout. Xanthine

inhibitors

oxidase inhibitors slow the enzyme xanthine oxidase, which
is involved in the production of uric acid.

xx
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Chapter 1

1

Introduction

Acute kidney injury (AKI) is the sudden deterioration of kidney function which affects at
least 10% of hospitalized patients.1–3 AKI associates with increased morbidity, mortality,
and health care costs exceeding $10 billion annually in the United States.4–7
Our understanding of AKI epidemiology is largely informed by studies conducted in
hospitalized and critically ill patients.1,3,4,8 Less is known about patients who present to
the emergency department (ED), have evidence of AKI, and are discharged home. A
discharge home may mean the ED health care staff felt the AKI was reversible and could
be managed as an outpatient in the community or it may represent an unrecognized
population at risk of adverse outcomes.
As of August 10, 2017, no study has described the characteristics and adverse outcomes
of patients discharged home from the ED with AKI in comprehensive detail, nor has any
study compared these outcomes to other relevant ED patient groups. To address this
knowledge gap, we conducted a population-based cohort study to describe the
characteristics and outcomes of this AKI subpopulation. To provide context to our
results, we used propensity score methods to investigate whether an ED discharge home
with AKI compared to an admission to hospital, or ED discharge home with no AKI, is
associated with an altered risk of 30-day all-cause mortality.
This thesis is structured into the following chapters: 2 Literature Review, 3 Rationale and
Research Questions, 4 Methods, 5 Results, and 6 Discussion. In Chapter 2, we provide an
explanation of normal kidney function and define AKI. We then describe our current
understanding of AKI epidemiology. Finally, we highlight a knowledge gap regarding
patients discharged home from the ED with AKI. In Chapter 3, we state our research
questions and rationale for each question. In Chapter 4, we provide a detailed summary of
our methods. In Chapter 5, we present our results with accompanying figures and tables.
In Chapter 6, we discuss our findings and their implications relative to our current
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understanding of AKI in the community and in hospital. Finally, we discuss the strengths
and weaknesses of this work and conclude with recommendations for future research.

3

Chapter 2

2

Literature Review

2.1 The Normal Kidney
2.1.1

Overview of Kidney Function

The kidney is a vital organ with several key functions. These functions include the
excretion of metabolic waste products such as urea and creatinine, regulation of fluid and
electrolytes such as sodium and potassium, and the production of hormones that regulate
local and systemic processes involved in hemodynamics, bone mineral metabolism, and
the production of red blood cells.9

2.1.2

Measurement of Kidney Function

The kidney is comprised of millions of nephrons, which are the main filtration units of
the kidney.9 The sum of all functioning nephron filtration rates is called the glomerular
filtration rate (GFR).10 Certain waste products of metabolism have specific properties that
make them suitable candidates as biomarkers to estimate the GFR.10 The most common
biomarker used by clinicians is serum creatinine (SCr). SCr is a byproduct of muscle
metabolism that is filtered and excreted unchanged by the kidneys.10 Despite the
availability of other biomarkers such as cystatin C, SCr remains the most convenient and
cost-effective test for measuring kidney function in routine care.11 SCr concentrations are
incorporated into an equation to calculate the estimated GFR (eGFR).10 The Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation is a recent and
accepted method of calculating the eGFR. Developed in 2009, the CKD-EPI equation has
replaced the Modification of Diet in Renal Disease (MDRD) equation because of greater
precision and accuracy.12 All GFR-estimating equations assume relative stability in SCr
concentrations over time and cannot be used to assess abrupt changes in kidney
function.10,13 Because of this major limitation, clinicians continue to rely on relative
changes in SCr concentrations to assess AKI.14
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2.2 Acute Kidney Injury
AKI is serious clinical condition defined by a sudden loss of kidney function, which
results in the rapid accumulation of waste products, fluids, and electrolytes.10 Acute
kidney injury replaces the term acute renal failure following the recognition that smaller
decrements in kidney function are clinically relevant.14 The term AKI will be used
throughout the entire thesis.

2.2.1

Definition of Acute Kidney Injury

The use of relative changes in SCr concentration is considered the standard of care for the
detection of AKI. Standardized, consensus definitions for AKI have been developed for
use in the general population (Table 2-1). The most recent consensus definition for AKI
was developed by the Kidney Diseases: Improving Global Outcomes (KDIGO) AKI
working group in 2012,14 adapted from two criteria: RIFLE (Risk, Injury, Failure, Loss,
End-stage renal disease) in 2004,15 and AKIN (Acute Kidney Injury Network) in 2007.16
Table 2-1: Diagnostic Criteria for Acute Kidney Injury
Criteria
Definition

RIFLE15
Relative
increase in SCr
from baseline
of ≥50%
developing
within 7 days

SCr criteria
AKIN16
Relative increase
in SCr of ≥26.5
µmol/L or ≥50%
from baseline
developing within
48 hours

KDIGO14
Absolute increase
in SCr of ≥26.5
µmol/L developing
within 48 hours or
relative increase
≥50% developing
within 7 days

Urine output
criteria
Urine output
of <0.5
mL/kg/hour
for >6 hours

Adapted from the 2012 KDIGO clinical practice guidelines for AKI.14

AKI can be diagnosed when one of the following criteria is met: (1) SCr increase of
≥26.5 µmol/L within 48 hours; (2) a 50% increase or more from baseline (compared to a
known or suspected baseline value) within seven days; (3) a reduction in urine output to
<0.5 mL/kg/day for at least six hours.14 AKI can be stratified into three stages of severity.
Stage 1 AKI is defined as a relative increase in SCr ≥50% to <100% within seven days,
an absolute increase in SCr of ≥26.5 µmol/L within 48 hours, or a decrease in urine
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output to <0.5 mL/kg/hour for 6 to <12 hours. Stage 2 AKI is defined as a relative
increase in SCr value of ≥100% to <200% from baseline within seven days or a reduction
in urine output to <0.5 mL/kg/hour for 12 to <24 hours. Stage 3 AKI is defined as a
relative increase in SCr value of >200% from baseline or an increase in SCr value to
≥354 µmol/L within seven days, or the initiation of dialysis (renal replacement therapy).

2.3 Acute Kidney Injury Epidemiology
AKI is a serious clinical condition that affects at least 10% of all patients in hospital.1–3,17
In the United States, the incremental health care costs attributed to AKI in hospitalized
patients are in excess of $10 billion per year.4 Morbidity and mortality associated with
AKI escalates with severity.4,8,18–20 Among patients who receive dialysis for the
management of their AKI, short-term mortality exceeds 50%.8,21 Large cohort studies
have also shown that AKI as defined by modest increments in SCr concentration (e.g.
increase by 50% or more) independently associates with a 3.5 day increase in hospital
length of stay and a 4.4-fold increase in mortality.4
Individuals who survive an episode of AKI during hospitalization remain at risk of short
and long-term adverse outcomes.7,18,22 Within the first 3 to 6 months, survivors of AKI
are at 10-fold greater risk of developing de novo chronic kidney disease (CKD), at 3-fold
greater risk of progression to end-stage kidney disease, and have double the risk of
death.20,23,24 In the long-term AKI is associated with an increased risk of coronary events
(non-fatal myocardial infarction, need for coronary angiogram, or coronary artery bypass
surgery),25,26 stroke,27 and hypertension.28 Despite accumulating evidence that AKI
survivors are a high risk group, follow-up care remains poor and inadequate.29–31

2.4 Emergency Department Setting
The ED is a common place for patients to seek health care. From 2015 to 2016, the
Canadian Institute for Health Information (CIHI) reported that 4,865,575 adults 20 years
and older visited an ED in Ontario, 556,786 (11.4%) of whom required admission to
hospital.32 The reasons for the ED visits varied widely, ranging from acute abdominal and
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pelvic pain (3.6%) to gastroenteritis (1.6%).32 The ED was also a point of access to
receive primary care for patients with non-urgent issues despite being registered with a
family physician.33,34
The ED is an environment where visits are brief and transient.35–37 Following their
clinical assessment, ED physicians are challenged with the task of determining the
disposition of the patient. The patient may be discharged home to the community with or
without outpatient follow-up, transferred to another hospital, or referred to another
medical service to be admitted to hospital. The final decision on disposition is influenced
by several patient-, physician-, facility-, and regional-related factors.38,39
The ED is a common clinical setting for patients to present with AKI,40,41 and studies
have primarily focused on patients admitted to hospital from the ED.42,43 However, in
some circumstances patients with AKI who present to the ED will be discharged home
rather than be admitted to hospital.

2.5 Patients Discharged from the Emergency Department
with Acute Kidney Injury
2.5.1

Search Strategy and Quality Assessment of Prior Studies

A single reviewer conducted a literature search to identify prior studies that described
patients discharged home from the ED with AKI. MEDLINE Ovid and Pubmed were
searched for relevant articles in March 2016. The search was updated on August 10,
2017. The final search strategy combined two previously published search strategies for
AKI- and ED-related studies (Appendix A).44,45 Key words included “communityacquired”, “outpatient”, “ambulatory care”, and “primary care” because patients
discharged home from the ED may be described in studies investigating communityacquired AKI. The reviewer also used the related articles option in Pubmed and searched
relevant review articles and reference lists of included articles.
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Our inclusion and exclusion criteria were developed a priori. Any study published in
English was eligible for review. Studies were excluded using any one of the following
criteria: (1) duplicate studies; (2) reviews, editorial articles, or consensus guidelines; (3)
pediatric (age less than 18 years) or non-human studies; (3) studies that did not describe
patients with AKI; (4) studies in which AKI did not occur in the ED setting; and (5)
studies that did not describe patients discharged home.
A single reviewer screened all citations for potentially relevant articles, reviewed full-text
articles for eligibility, and then abstracted the data from eligible studies. The same
reviewer evaluated the quality of individual studies using the Downs and Black quality
assessment method, a list of 27 criteria to evaluate both randomized and non-randomized
studies.46 This scale assesses the completeness and clarity of study reporting, external
validity, internal validity (e.g. bias and confounding), and power. The tool was modified
slightly for use in our review. Specifically, the scoring for question 27 dealing with
statistical power was simplified to a choice of awarding either 1 or 0 points depending on
whether there was sufficient power to detect a clinically important effect. On the
modified scale, we gave all included studies a score from 0 to 28, grouped into the
following four quality levels: excellent (26 to 28), good (20 to 25), fair (15 to 19) and
poor (14 or less).

2.5.2

Summary of Previous Literature

A study flow diagram of the literature search is shown in Figure 2-1 and from the
beginning excludes the citation related to this thesis.47 A single reviewer screened 11,465
articles for potentially relevant citations and selected 514 studies for evaluation. There
were 509 articles excluded, leaving five studies which distinctly described patients who
visited an ED, had evidence of AKI, and were discharged home (Table 2-2).48–52
Three studies were from the United Kingdom,49–51 one was from the United States,48 and
one was from Canada.52 A total of 3031 patients visited the ED, had evidence of AKI, and
were discharged home. In all five studies, patients discharged from the ED with AKI
were described as a subgroup of larger patient population. The 2013 study by Roghmann
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et al. showed 71 (0.01%) of 1,066,135 patients presenting to the ED with lower urinary
tract symptoms were discharged home with AKI.48 In 2014, Talabani et al. identified 230
consecutive patients in the United Kingdom with community-acquired AKI who visited
either a primary care physician or acute care centre (i.e. emergency department).49 The
mean age of the entire cohort was 70 years and the 90-day mortality was 17%. In a subset
of 119 patients who visited an acute care centre, 49 (41%) were discharged home. The
2017 study by Hazara et al. used an electronic AKI alerting system to identify 1277 AKI
episodes in 1185 patients who visited the ED.51 The mean age was 72 years, 50% were
male, and the 30-day mortality was 25%. The authors also found 13% (161) of all AKI
alerts represented ED patients discharged home. However, for all three studies, baseline
characteristics and outcomes specific to patients discharged home from the ED with AKI
were lacking.
The 2016 study by Holmes et al. examined 9375 patients with AKI assessed in accident
and emergency or acute assessment units. The mean age ranged between 68 and 71 years
and 40 to 49% had pre-existing CKD. In a subgroup of 2719 patients (29%) discharged
home, the 90-day mortality was 10 to 15%.50 There was no additional information on
baseline characteristics. In 2017, Scheuermeyer et al. studied 1651 consecutive ED
patient visits over a one-week period, 90 (6%) of whom were diagnosed with AKI.52
Among patients with AKI, 31 (34%) were discharged home. The age ranged between 29
and 93 years, co-morbidities were described in select cases, and there were no deaths
within 30 days of an ED discharge home. Only four patients (13%) had renal-specific
follow up.
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Figure 2-1: Literature Review Flow Diagram

Abbreviations: AKI, acute kidney injury; ED, emergency department.
a
Details of the literature review search strategy is shown in Appendix A. The numbers shown in the figure exclude the
citation related to this thesis.47

Table 2-2: Summary of Studies Examining Patients Discharged Home from the Emergency Department with Acute Kidney Injury
Author

Year

Location

Population

Description

Key findings

Limitations

Quality
score
(0-28)a
18

Roghmann et
al.

2013

United
States,
2006-2009

1,178,423
patients
presenting to
the ED with
LUTS

Of the 1,066,135
patients with
LUTS discharged
home from the ED,
71 (0.01%) had
AKI.

No baseline
characteristics
specific to AKI
patients.

Talabani et
al.

2014

United
Kingdom
(Cardiff),
Apr 2009

230 patients
identified with
CA-AKI on
health region

119 patients
diagnosed with
AKI in an acute
care setting (ED),
with 49 (41%)
discharged home.

Descriptive study
only. No baseline
characteristics or
outcomes specific
to this subgroup of
patients with CAAKI.

17

Holmes et al.

2016

United
Kingdom
(Wales),
Mar - Aug
2015

17,689 AKI
episodes
generated using
e-alert system
in the health
region

Patients stratified
by ED disposition
(admitted vs.
discharged),
various outcomes
defined as adverse
events, (e.g. ICD-9
code for AKI: 584)
Patients stratified
by type and
location of CAAKI diagnosis.
AKI defined by
SCr values using
KDIGO criteria.
Outcomes included
mortality, CKD
progression, and
renal recovery.
Patients stratified
by either CA-AKI
vs HA-AKI, and
AKI severity. AKI
defined using
KDIGO criteria.
Outcome was

Of the 9375 AKI
episodes diagnosed
in the ED, 2719
(29%) were
discharged home
(similar for all
AKI stages),

Descriptive study.
Except for age and
CKD, no other
baseline
characteristic for
our patient
population of

16

10

Hazara et al.

2016

Scheuermeyer 2017
et al.

United
Kingdom
(Kingstonupon-Hull),
Nov 2013 –
Apr 2014

1277 AKI
episodes
generated in
1185 ED
patients using
an e-alert
system.

Canada
1651 unique
(Vancouver), patient ED
Jan 2014
visits screened
for AKI in two
EDs over a 1week period

location of
diagnosis and 90day mortality.
AKI defined using
KDIGO criteria.
Outcome was 30day mortality.

respectively. The
90-day mortality
was 10-15%.
Of the 1277 AKI
episodes identified
in the ED, 161
(13%) AKI
episodes (98%
stage 1 AKI)
represented
patients discharged
home.
AKI defined using Of the 90 patients
KDIGO criteria.
who had AKI, 31
Outcomes included (34%) were
follow-up SCr
discharged home.
testing, mortality,
Four patients
and need for renal (13%) were
replacement
deemed to have
therapy at 30 days. appropriate followup and none died.
ED diagnosis
provided, detailed
chart review for
each patient.

interest was
present.
Descriptive study.
No detailed
baseline
characteristics. 30day mortality not
described for
subgroup.

15

Small study.
Clinical vignette
for each case. No
detailed list of
baseline
characteristics for
subgroup.

14

Abbreviations: AKI, acute kidney injury; CA-AKI, community-acquired acute kidney injury; CKD, chronic kidney disease; ED, emergency department; HA-AKI, hospitalacquired acute kidney injury; ICD, International Classification of Diseases; KDIGO, Kidney Disease: Improving Global Outcomes; LUTS, lower urinary tract symptoms; SCr,
serum creatinine.
a
We evaluated the quality of individual studies using the Downs and Black quality assessment method, which is a list of 27 criteria to evaluate both randomized and nonrandomized trials.46 This scale assesses the completeness and clarity of study reporting, external validity, internal validity (e.g. bias and confounding) and power. The tool was
modified slightly for use in our review. Specifically, the scoring for question 27 dealing with statistical power was simplified to a choice of awarding either 1 or 0 points
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depending on whether there was sufficient power to detect a clinically important effect. On the modified scale, we gave all included studies a score from 0 to 28, grouped into
the following four quality levels: excellent (26 to 28), good (20 to 25), fair (15 to 19) and poor (14 or less).
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Chapter 3

3

Rationale and Research Questions

3.1 The Need for Research
No study has investigated the characteristics and outcomes of patients discharged home
from the ED with AKI in detail nor has any study provided context for these outcomes by
comparing this group to other relevant ED subpopulations. A better understanding of this
patient population is required.
The research questions and hypotheses for this study are separated into (1) a descriptive
analysis of the characteristics and outcomes of patients discharged home from the ED
with AKI (Chapter 3.2.1) and (2) a propensity score matching analysis (Chapter 3.2.2).

3.2 Research Questions and Hypotheses
3.2.1
3.2.1.1

Descriptive Analysis
Primary Questions

1) In the ED setting, what are the characteristics of patients discharged home with AKI?
Hypothesis: Co-morbid conditions, such as diabetes, hypertension, and CKD and the
use of certain medications such as angiotensin-converting enzyme inhibitors,
angiotensin II receptor blockers, and diuretics will be common in this patient
population.
2) In the ED setting, what is the 30-day risk of all-cause mortality in patients discharged
home with AKI?
Hypothesis: Based on our literature review,48–52 the 30-day risk of all-cause mortality
is estimated to be between 0% and 15%. This risk will increase with AKI severity.
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3.2.1.2

Secondary Questions

1) In the ED setting, what is the 30-day risk of receipt of hospital-based acute dialysis in
patients discharged home with AKI?
Hypothesis: Our literature search did not inform the expected rate for the receipt of
hospital-based acute dialysis. Given these patients are discharged home rather than
admitted to hospital, the receipt of hospital-based acute dialysis is expected is to be
low, and increase with AKI severity.
2) In the ED setting, what is the 30-day risk of five additional outcomes: (1) need for
subsequent hospitalization after an ED discharge home, (2) at least one outpatient
physician visit (family physician, internist, nephrologist, or urologist), (3) at least one
outpatient SCr test, (4) at least one outpatient urine test for protein, and (5) total
health care costs?
Hypothesis: Our literature search did not inform the expected rate for these additional
outcomes. However, these outcomes are expected to increase with AKI severity.

3.2.2
3.2.2.1

Propensity Score Matching Analysis
Primary Questions

1) In the ED setting, does a group of patients discharged home with AKI compared to a

group of patients admitted to hospital with AKI with similar baseline characteristics
have an altered 30-day risk of all-cause mortality?
Hypothesis: An ED discharge home with AKI will be associated with a lower risk of
mortality compared to a hospital admission with AKI. It is expected that critically ill
patients will be appropriately admitted to hospital for ongoing management. It is
unlikely that an ED discharge home with AKI would confer a higher risk of mortality
compared to a hospital admission with AKI.
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2) In the ED setting, does a group of patients discharged home with AKI compared to a
group of patients discharged home with no AKI with similar baseline characteristics
have an altered 30-day risk of all-cause mortality?
Hypothesis: An ED discharge home with AKI will be associated with a higher risk of
mortality compared to an ED discharge home with no AKI. It is expected our findings
to be similar in studies that compared hospitalized patients with AKI versus no AKI.

3.2.2.2

Secondary Questions

1) In the ED setting, does a group of patients discharged home with AKI compared to a
group of patients admitted to hospital with AKI with similar baseline characteristics
have an altered 30-day risk of receipt of hospital-based acute dialysis?
Hypothesis: An ED discharge home with AKI will be associated with a lower risk of
receipt of hospital-based acute dialysis compared to a hospital admission with AKI.
2) In a subgroup analysis, is the association between an ED discharge home with AKI
(versus a hospital admission with AKI) and 30-day risk of all-cause mortality
modified by AKI stage?
Hypothesis: Compared with a hospital admission with AKI, the relative association
between an ED discharge home with AKI and all-cause mortality may be attenuated
with an increase in AKI stage. Based on previous literature, higher stages of AKI
associate with increased mortality in a group patients with AKI who are managed as
outpatients.49,53
3) In the ED setting, does a group of patients discharged home with AKI compared to a
group of patients discharged home with no AKI with similar baseline characteristics
have an altered 30-day risk of receipt of hospital-based acute dialysis?
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Hypothesis: An ED discharge home with AKI will be associated with a higher risk of
receipt of hospital-based acute dialysis compared to an ED discharge home with no
AKI.
4) In a subgroup analysis, is the association between an ED discharge home with AKI
(versus an ED discharge home with no AKI) and the risk of 30-day all-cause
mortality modified by the presence of pre-ED visit CKD?
Hypothesis: Compared with an ED discharge home with no AKI, an ED discharge
home with AKI will be associated with a higher risk of all-cause mortality by the
presence of CKD.54,55
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Chapter 4

4

Methods

4.1 Study Design and Setting
We conducted a population-based, retrospective cohort study of adults 40 years and older
from June 1, 2003 to March 31, 2012 in Southwestern Ontario, Canada at the Institute for
Clinical Evaluative Sciences (ICES) Western facility. Southwestern Ontario has
approximately 1.6 million residents with universal access to hospital care and physician
services through the Ontario Health Insurance Plan (OHIP).56 Universal prescription drug
coverage is available for adults 65 years and older through the Ontario Drug Benefit
(ODB) program. Ontario’s linked health administrative databases provide research
studies with rich information, large sample sizes, and complete short- and long-term
follow-up. This study followed the Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) guidelines for reporting observational studies (Appendix
B).57

4.2 Ethics
Our study was approved by the research ethics board at Sunnybrook Health Sciences
Centre in Toronto, Ontario. Participant informed consent was not required for this study.
However, to comply with privacy regulations for minimizing the chance of patient reidentification, results were suppressed in cells with five or fewer patients (reported at ≤5).
The total number of patients was not reported (NR) if there were other calculations that
could also result in the re-identification of five or fewer patients.

4.3 Data Sources
We ascertained patient, ED, and hospital characteristics, prescription drug information,
and outcome data from 13 health administrative and laboratory databases. These datasets
were linked using unique, encoded identifiers and analyzed at the ICES Western facility.
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4.3.1

Administrative Databases

Ontario Registered Persons Database (RPDB): We obtained patient demographics (age,
sex, and vital status), income (averaged quintiles of neighbourhood income), and
residential location (urban vs. rural). Vital statistics are available for all Ontario residents
who have ever been issued a health card. We used vital statistics information to ascertain
the outcome of all-cause mortality.
Ontario Drug Benefit (ODB): The ODB database contains records of all outpatient drug
prescriptions dispensed to residents 65 years and older. Drug prescription accuracy in the
ODB database is high, with an error rate of less than 1%.58 We used this database to
obtain baseline medication use for ODB program eligible individuals in the 120 days
prior to the ED visit date (referred to as the cohort entry or index date) and to determine
residential status (community-dwelling vs. long-term care).
Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD) and
National Ambulatory Care Reporting System (NACRS): We identified diagnostic and
procedural information on ED visits from NACRS and hospitalizations from CIHI-DAD.
Diagnostic codes were based on the International Classification of Diseases (ICD), 9th
revision (ICD-9; pre-2002) and 10th revision (ICD-10; post-2002). Procedural codes
were derived from the CIHI-DAD Canadian Classification of Health Interventions (CCI),
Canadian Classification of Diagnostic, Therapeutic and Surgical Procedures (CCP)
(Appendix C). We also used the CIHI-DAD and NACRS to obtain information on health
care utilization (Appendix D), application of patient exclusion criteria (Appendix E), and
health care costs associated with ED visits and hospitalizations (Appendix F).
Ontario Health Insurance Plan (OHIP): The OHIP database contains information on
physician claims for all health care services (inpatient and outpatient) using fees outlined
in the OHIP Schedule of Benefits and ICD-9 diagnostic codes. The sensitivity of
information recorded in the OHIP database is over 90% when procedural codes
abstracted from the database are compared to the actual code recorded on the chart by the
physician.59 In addition to diagnostic (ICD-9 and ICD-10) and procedural information
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(CCI and CCP) obtained from CIHI-DAD and NACRS, we also used the OHIP database
to develop our patient exclusion criteria and obtain additional information on baseline comorbidities, health care utilization, and outcome variables (Appendix C–F).
Institute for Clinical Evaluative Sciences Physician Database (IPDB): The IPDB records
contains demographic, specialty, education, and practice information on all practicing
physicians in Ontario. We used this database to measure the number of family
physician/general practitioner, nephrologist, internal medicine, and urologist visits and to
determine ED physician practicing specialty (emergency medicine, family medicine, and
other) (Appendix D).

4.3.2

Laboratory Databases

We used two laboratory databases to obtain outpatient and inpatient test results for
Ontario residents.
Cerner: Cerner is one of the largest electronic health record vendors in the world
(Missouri, United States of America).60 Thirteen hospitals in Southwestern Ontario share
the same electronic health record. The Cerner database contains outpatient, ED, and
inpatient laboratory results for five blood tests (SCr, sodium, potassium, creatine kinase,
and glucose) for adults 40 years and older from June 1, 2002 and March 31, 2012. We
used this database to ascertain SCr, sodium, and potassium measurements.
Dynacare Medical Laboratories: The Dynacare database contains outpatient laboratory
test results from all Dynacare laboratory locations across Ontario since 2002. Dynacare is
one of the three largest laboratory providers in Ontario, contains records on over 59
million tests each year, and represents approximately one-third of all Ontario residents.61
Dynacare does not represent testing in the ED or hospital. We used Dynacare to ascertain
outpatient SCr and urine protein measurements (albumin, total protein, and dipstick) to
define baseline kidney function and outcome variables (Appendix F).
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Due to the inherent limitations of these two databases, this cohort study was restricted to
patients 40 years and older who visited a Southwestern Ontario hospital equipped with
the Cerner electronic health record and used Dynacare Medical Laboratories for
outpatient testing.

4.3.3

Databases for Health Care Cost Estimation

We used six data sources in addition to the CIHI-DAD, NACRS, OHIP, and ODB
databases to estimate total health care costs incurred by Ontario residents.62
Assistive Device Program (ADP): The ADP database is operated by the Ministry of
Health and Long-Term Care and records information on consumer-centered support to
Ontario residents with long-term disabilities such as personalized assistive devices.
Client Agency Program Enrolment (CAPE): The CAPE database accounts for the
services provided by multidisciplinary family health teams comprised of family
physicians, nurses, and other allied health care professionals.
Continuing Care Reporting System (CCRS): The CCRS for chronic care database records
clinical and demographic information on residents receiving facility-based continuing
care services, including hospital-based continuing care (complex continuing care,
extended/chronic care) and residential care providing 24-hour nursing services (nursing
home, home for the aged).
Home Care Database (HCD): The HCD is derived from either the Ontario Association of
Community Care Access Centres or the Ministry of Health and records information on
individuals requiring any home care service provided by the province’s Community Care
Access Centres.
National Rehabilitation Reporting System (NRS): The NRS database collects, processes,
and analyzes adult inpatient rehabilitation services at the hospital, regional, and
provincial/territorial levels.
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Ontario Mental Health Reporting System (OMHRS): The OMHRS database collects data
on patients in adult designated inpatient mental health beds, which includes beds in
General, Provincial Psychiatric, and Specialty Psychiatric facilities.

4.4 Patients
4.4.1

Inclusion Criteria

We established a cohort of Ontario adults 40 years and older who visited an ED for any
reason and had at least one SCr measurement at the ED visit between June 1, 2003 and
March 31, 2012. The date of the ED visit served as the cohort entry or index date.

4.4.2

Exclusion Criteria

Before matching (Chapter 4.7), we excluded the following patients from the cohort who:
(1) died on arrival or during the ED visit, (2) did not have a SCr measurement 7 to 365
days prior to the ED visit (pre-ED visit baseline) as a baseline SCr measurement was
needed to diagnose AKI in the ED, (3) received dialysis one year prior to the ED visit as
AKI would not be relevant on dialysis and to ensure stable kidney function after the
discontinuation of dialysis, (4) received a kidney transplant in the five years prior to the
ED visit to ensure AKI was not related to transplant rejection, (5) spent more than 48
hours in the ED to exclude those without a disposition plan, (6) left against medical
advice or without being seen by an ED physician, (7) were transferred to another facility,
or (8) received palliative care 30 days prior to or 14 days after the ED visit to exclude
those who did not receive active medical management.

4.4.3

Main Cohort and Referent Groups

Following the application of our inclusion and exclusion criteria, patients were assigned
to one of three groups based on AKI and ED disposition. The main cohort was a group of
patients discharged home from the ED with AKI (Figure 5-1). The two referent ED
groups were patients (1) admitted to hospital from the ED with AKI (Figure 5-2) and (2)
discharged home from the ED with no AKI (Figure 5-3).
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For all ED visits with AKI, we excluded patients with an improvement in AKI severity
during the ED visit. For an ED discharge home with AKI, we excluded those assigned a
main ED diagnosis of AKI (ICD-10 code: N17) to concentrate on patients less likely to
be treated and resolved prior to discharge home. For ED visits with no AKI, we selected
the first ED visit in which the individual had both ED and pre-ED visit baseline SCr
measurements.
If an individual had multiple ED SCr measurements, we selected the highest value. If
multiple pre-ED visit baseline SCr values were available, we selected the most recent one
prior to the ED visit. Pre-ED visit baseline SCr measurements were chosen no earlier
than seven days prior to the ED visit to avoid potentially unstable baseline values that
may occur prior to an acute illness. There was no crossover of patients between groups.
Preference was given to the group discharged home from the ED with AKI if patients
were also eligible for one of the other two groups.

4.5 Characteristics
4.5.1

Baseline Characteristics

We considered several patient demographics, co-morbid conditions, medication use in
ODB eligible patients, prior health care utilization, pre-ED visit baseline kidney function,
and ED visit patient and facility characteristics as baseline characteristics in this study
(Appendix G). We assessed baseline co-morbid conditions in the five years prior to the
index date.
For ODB program eligible patients, we assessed medication use in the 120 days prior to
the index date. We evaluated prior health care use including ED or hospital visits,
physician visits, and diagnostic or screening tests conducted in the previous 365 days.

We used the Charlson co-morbidity index and Aggregated Diagnosis Groups (ADG)
point score to measure the burden of co-morbidity in our patient population. The
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Charlson co-morbidity index is based on the International Classification of Diseases
diagnosis codes found in administrative data.63 Derived from the Charlson score, the
metric measures the general co-morbidity based on the relative effects of a combination
of diseases or risk factors on outcomes for a given individual to show the expected oneyear mortality.64 The ADG point score, derived from the John Hopkins Adjusted Clinical
Groups® system,65,66 is a weighted measure of health care utilization as a proxy measure
for co-morbidity and accounts for the duration of condition, severity of condition,
diagnostic certainty, etiology of the condition, and specialty care involvement.

4.6 Kidney Function
4.6.1

Acute Kidney Injury

Acute kidney injury was defined as a relative increase in SCr by 50% or more, or an
absolute increase in a SCr value of 26.5 µmol/L or more, from the most recent pre-ED
visit baseline SCr. We adapted the 2012 KDIGO guidelines to identify and stage patients
according to AKI severity.14 Stage 1 AKI was defined as evidence of a relative increase
in SCr value of ≥50% to <100% or ≥26.5 µmol/L from baseline; stage 2 AKI: evidence of
a relative increase in SCr value of ≥100% to <200% from baseline; and stage 3 AKI:
evidence of a relative increase in SCr value of >200% from baseline or an increase in SCr
value to ≥354 µmol/L or the initiation of renal replacement therapy. Urine output was not
available in our data sources.
We defined AKI using SCr measurements because our group showed that the ICD-10
diagnostic code N17 demonstrated poor sensitivity in the identification of AKI in ED
setting (7-30%).41 Validation of the AKI code in a subset of patients discharged home
from the ED with AKI is unknown and may demonstrate even lower sensitivities.
Reliance of ICD-10 diagnostic codes would likely result in the exclusion of many
patients who truly had AKI, as well as falsely identifying some patients as not having
AKI when they in fact had AKI.
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4.6.2

Baseline Kidney Function

We used pre-ED visit SCr measurements to assess baseline kidney function and used the
CKD-EPI equation to calculate the eGFR.12 All eGFR values were reported in
mL/min/1.73m2. CKD was defined as an eGFR<60.67 We also stratified baseline kidney
function into the following groups: normal renal function, stage 1 or 2: eGFR≥60
mL/min/1.72m2, stage 3a: 45≤eGFR<60, stage 3b: 30≤eGFR<45, stage 4 or 5: eGFR<30
but not on dialysis. Patients with an eGFR 15 to <30 were combined with patients with an
eGFR <15 to comply with ICES privacy regulations on reporting small numbers.

4.7 Propensity Score Matching
To provide context for our primary and secondary outcome (Chapter 4.8), we conducted
two separate propensity score matching analyses. In the first matching study, we
compared patients discharged home from the ED with AKI to patients admitted to
hospital from the ED with AKI (referred to as the AKI subpopulation). In the second
matching study, we compared patients discharged home from the ED with AKI to
patients discharged home from the ED with no AKI (referred to as the discharged
subpopulation).
We used propensity scores to achieve balance on measured baseline characteristics and
eliminate systematic differences between comparison groups of each matching study
(Appendix G).68–71 Propensity score is defined as the probability (“propensity”) of an
exposure, treatment, or intervention for an individual given a set of measured, relevant
characteristics.70,71 Propensity scores are often estimated using a multivariable logistic
regression model. Individuals are then matched based on the same or similar propensity
scores,72 which is described in Chapters 4.7.1 and 4.7.2.

4.7.1

AKI Subpopulation

We formed a matched set of ED patients with AKI in two groups with a similar ED
disposition probability (discharged home vs. admission to hospital) for a given set of
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baseline covariates.68–71 We estimated propensity scores using a multivariable logistic
regression model with 92 baseline characteristics selected because of potential influence
on outcomes between comparison groups (Appendix G).71,73,74 We matched one ED
patient discharged home with AKI (comparison group) to one ED patient admitted to
hospital with AKI (referent group) on the logit of the propensity score [with a specified
caliper width of ± 0.2 times the standard deviation (SD)] and AKI stage (1, 2, or 3).72
Several matching techniques are available, including individual versus frequency
matching,70 and greedy versus optimal matching.71 The implementation of greedy
matching is simple, straightforward, and efficient in studies involving large health care
administrative databases and performs as well as optimal matching in forming balanced
groups.75 For these reasons, we selected the greedy matching technique. One ED patient
discharged home with AKI was first selected at random to the nearest patient admitted to
hospital with AKI within the specified caliper distance, even if there was a better match
for a subsequent ED patient discharged home with AKI.71 The process was repeated for
ED patents with AKI until patients admitted to hospital had been matched to ED patients
discharged home, or until the list of patients discharged home for whom a matched
patient admitted to hospital could be found had been exhausted. Patients were matched
without replacement and those who were not matched successfully were excluded from
the analysis.

4.7.2

Discharged Subpopulation

We formed a matched set of ED patients discharged home in two groups with a similar
probability of having AKI for a given set of baseline covariates.68–71 We estimated
propensity scores using a multivariable logistic regression model with 91 baseline
characteristics (Appendix G).71,73,74 We matched one ED patient discharged home with
AKI (comparison group) to one ED patient discharged home with no AKI (referent
group) on the logit of the propensity score (with a specified caliper width of ± 0.2 times
the SD) and CKD stage using eGFR categories: ≥60 mL/min/1.72m2, 45≤eGFR<60;
30≤eGFR<45, 15≤eGFR<30, and an eGFR<15, but not on dialysis. We used the same
matching techniques and preferences described for the AKI subpopulation.
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4.7.3

Incomplete or Missing Data

Information on medication use was not be available in patients under 65 years of age as
they are not eligible for universal drug coverage through the ODB program. A large
proportion of ED patients discharged home with AKI would be excluded from the
analysis had we restricted our cohort to individuals 65 years and older. However, our
propensity score includes ODB program eligibility and several co-morbid conditions for
which these missing medications would be indicated. For these reasons, we included ED
patients with AKI regardless of age and accepted the limitations associated with missing
medication information in patients under 65 years of age.
We anticipated all baseline characteristics to be complete with a few exceptions. First,
income quintile was expected to be missing in less than 2% of patients.41,76,77 Second,
location of residence was expected to be missing in up to 0.2%.78 To account for
incomplete or missing data before matching, we imputed ‘no’ for missing rural residency
status and the middle quintile for missing income (income quintile 3). We also imputed
the median value for missing serum sodium and potassium concentrations.79 The
proportion of missing serum sodium and potassium concentrations was expected to be
low because physicians routinely request serum sodium, potassium, and creatinine
collectively in a panel of tests.

4.8 Outcomes
4.8.1

Primary Outcome

The primary outcome for all analyses was all-cause mortality. We restricted our analysis
to 30 days after the index date, which is an acceptable timeframe to attribute an outcome
to the ED visit.80 All-cause mortality was obtained from vital statistics in the RPDB. The
mortality flag in the RPDB has a sensitivity of 94% and a positive predictive value of
100%.81
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4.8.2

Secondary Outcome

The secondary outcome for all analyses was the receipt of hospital-based acute dialysis.
We restricted our analysis to 30 days after the index date. Physicians report billing and
procedural codes related to the initiation of hospital-based acute dialysis. Dialysis billing
and procedural codes in the setting of AKI have a specificity of greater than 94% (median
99%).82

4.8.3

Additional Outcomes

As outlined in Chapter 3.2.1.2, we assessed five additional outcomes for the main cohort
of patients discharged from the ED with AKI. We did not assess these outcomes for the
two propensity score matching analyses. The five additional outcomes were (1)
hospitalization after an ED discharge home, (2) at least one outpatient physician visit
(family physician, internist, nephrologist, or urologist), (3) at least one outpatient SCr
test, (5) at least one outpatient urine test for protein, and (5) total health care costs
(Appendix F). We restricted our analysis to 30 days after the index date for all five
additional outcomes. We used an ICES macro to estimate total health care cost associated
with health care use (Appendix F).62 Cost was reported in Canadian dollars and adjusted
for inflation to the year 2013.

4.9 Statistical Analyses
4.9.1

All Analyses

We compared baseline characteristics using standardized differences. This metric
compares two group means relative to a pooled standard deviation. A standardized
difference of 10% or greater is considered meaningful,83 and it is preferred over
hypothesis testing (using P values) for large samples because it is not influenced by
sample size.84–86 In propensity score matching studies with large groups, one can compare
balance in characteristics in both an unmatched and matched sample.85,86
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4.9.2

AKI Subpopulation

We estimated propensity scores using 92 baseline characteristics (Appendix G). SCr at
ED visit and AKI stage were variables in the propensity score specific to the AKI
subpopulation. ED length of stay was not included because it is dependent on when the
patient physically leaves the ED. The transfer of care from the ED physician to an
admitting service may have occurred several hours before the patient was physically
moved to a hospital bed. Therefore, ED length of stay will always differ between these
two groups.
We estimated the relative risk (RR) and 95% confidence intervals (CI) for our primary
and secondary outcome using a modified Poisson regression model that accounted for
matched data.87,88 Compared to the odds ratio, the RR is a more intuitive measure of
effect and does not overestimate risk with increasing frequency of the outcome.89 Patients
admitted to hospital from the ED with AKI served as the referent group. We also
evaluated the association between ED disposition (discharge home vs. admission to
hospital) and our primary outcome in a pre-specified subgroup defined by AKI stage
(Chapter 4.6.1).14 We determined interaction P values by including interaction terms in
the modified Poisson regression model.

4.9.3

Discharged Subpopulation

We estimated propensity scores with 91 baseline characteristics, 90 of which were
identical to those used in the AKI subpopulation (Appendix G). ED length of stay was a
variable in the propensity score specific to the discharged subpopulation. Because this
analysis compared patients with AKI versus no AKI, SCr at ED visit and AKI stage were
not included in the propensity score.
We estimated the RR and 95% CI for our outcomes using a modified Poisson regression
model that accounted for matched data.87,88 Patients discharged home from the ED with
no AKI served as the referent group. We also evaluated the association between AKI and
our primary outcome in a pre-specified subgroup defined by CKD stage (Chapter
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4.6.2).67 We determined interaction P values by including interaction terms in the
modified Poisson regression model.
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Chapter 5

5

Results

5.1 Descriptive Analysis
5.1.1

Characteristics of Patients Discharged Home from the
Emergency Department with Acute Kidney Injury

There were 6346 patients discharged home from the ED with AKI included in the cohort
over a 10-year period (Figure 5-1 and Table 5-1). Among these patients, 6012 (94.7%)
had stage 1, 290 (5.2%) had stage 2, and 44 (0.7%) had stage 3 AKI. The mean (SD) age
was 69 (14) years, 46.5% were female, and 15.3% lived in a rural residence. The most
common pre-existing co-morbidities were hypertension (75.4%), CKD (38.2%), diabetes
(37.9%), coronary artery disease (34.0%), heart failure (~21.7%), and major cancer
(16.6%). There were 4605 (72.6%) patients with universal drug coverage through the
ODB program and they were prescribed a median of five medications in the 120 days
prior to the ED visit. The most commonly prescribed medications were angiotensinconverting enzyme inhibitors or angiotensin receptor blockers (59.7%), non-potassium
sparing diuretics (56.7%), statins (47.2%), antibiotics (44.3%), beta-adrenergic
antagonists (38.7%), and proton pump inhibitors (35.9%). Non-steroidal antiinflammatory drugs were prescribed in 19.4% of patients.
Before the index date, there were 1114 (17.6%) patients in the previous 30 days and 3624
(57.1%) patients in the previous 31 to 365 days who had at least one ED visit. There were
481 (7.6%) patients in the previous 30 days and 1933 (30.5%) patients in the previous 31
to 365 days who required at least one hospitalization. In the 365 days before the index
date, 98.5% of patients had at least one family physician visit. Outpatient clinic visits
with a general internist (23.2%), nephrologist (~4.6%), and urologist (17.8%) were less
common. The most frequently ordered diagnostic test, procedure, or intervention in the
previous 365 days was an abdominal ultrasound (24.1%). The median [interquartile range
(IQR)] pre-ED visit baseline SCr concentration was 87 (71-112) µmol/L and was
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measured a median (IQR) 106 (44-207) days prior to the index date. A urine albumin-tocreatinine ratio (ACR) was measured in 26.6% of patients with approximately 10%
having micro- or macroalbuminuria.
During the index ED visit, the majority (80.6%) of patients were assigned to urgent or
emergent triage acuity scores [Canadian Triage Acuity Scale (CTAS) 1 to 3]. The 90th
percentile for ED length of stay was 8 to 9 hours. The median (IQR) ED SCr
concentration was 129 (109-162) µmol/L. The three most frequent main diagnoses
assigned by ED physicians were throat or chest pain (8.1%), abdominal or pelvic pain
(7.0%), and renal colic (4.9%) (Appendix H).
Income quintile was not available for 99 (1.6%) patients. Serum potassium and sodium,
both measured in a panel of electrolytes, were not available for 492 (7.8%) patients.

5.1.2

Characteristics by Acute Kidney Injury Severity

Cohort characteristics by AKI stage are shown in Table 5-1. Consistent with the
diagnostic criteria for AKI, ED visit SCr concentrations increased with AKI stage.
Compared to patients with stage 1 AKI, patients with stage 2 AKI were more likely to be
female, have lower income, reside in long-term care, have dementia, be prescribed
immunosuppressive medications and potassium-sparing diuretics, and have lower pre-ED
visit baseline SCr concentrations. They were less likely to have coronary artery disease,
CKD, and heart failure, be prescribed beta-adrenergic antagonists, oral hypoglycemic
agents or insulin, and xanthine oxidase inhibitors or uricosuric agents, be seen by a
urologist, have cardiac imaging, and be assigned an emergent triage acuity level (CTAS 1
or 2).
Compared to patients with stage 1 AKI, patients with stage 3 AKI were younger and
more likely to be female, have higher income, hypertension, major cancer, and an
Aggregated Diagnosis Group (ADG) point score of ≥6. Although these patients were
prescribed fewer medications in the previous 120 days, they were more likely to be
prescribed antibiotics, antidepressants, non-potassium sparing diuretics, non-steroidal
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anti-inflammatory drugs, and proton pump inhibitors. There were also more likely to
have a remote pre-ED visit baseline SCr measurement, lower serum sodium
concentration, require hospitalization in the previous 30 days, have a previous abdominal
ultrasound, and be assigned a less urgent triage acuity level (CTAS 4 or 5). They were
less likely to have coronary artery disease, dementia, and diabetes, be prescribed calcium
channel blockers, oral hypoglycemic agents or insulin, and statins, have an ED visit or
hospitalization in the previous 31 to 365 days, be seen at least once by a family physician,
and be assigned a CTAS of 1 or 2.
Compared to patients with stage 2 AKI, patients with stage 3 AKI were younger and
more likely to have higher income, hypertension, a Charlson co-morbidity index of ≥3,
and an ADG point score of ≥6. Although these patients were prescribed fewer
medications in the previous 120 days, they were more likely to be prescribed antibiotics,
antidepressants, beta-adrenergic antagonists, non-steroidal anti-inflammatory drugs, and
proton pump inhibitors, have a higher pre-ED visit baseline SCr concentration, higher ED
serum potassium concentration, lower ED serum sodium concentration, have a previous
abdominal ultrasound, require hospitalization in the previous 30 days, be seen at least
once by a urologist, and be assigned a CTAS of 4 or 5. They were less likely to live in a
rural residence, have dementia and diabetes, be prescribed calcium channel blockers,
corticosteroids, and statins, have an ED visit or hospitalization in the previous 31 to 365
days, be seen at least once by a family physician, and be assigned a CTAS of 3.
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Figure 5-1: Selection of Cohort of Patients Discharged Home from the Emergency
Department with Acute Kidney Injury from 2003 to 2012

Abbreviations: AKI, acute kidney injury; ED, emergency department; ICD, International Classification of Diseases;
SCr serum creatinine.
a
Patients were excluded in order as listed.
b
We selected the most recent pre-ED visit baseline SCr measurement.
c
If an individual had more than one ED visit with AKI, we selected the first ED visit.

Table 5-1: Baseline Characteristics of Patients Discharged Home from the Emergency Department with Acute Kidney Injury
All patients
Cohort size
Demographics
Age, in years
Mean (SD)
Median (IQR)
40 to <65
65 to <80
≥80
Sex, female
Year of cohort entry
2003 to 2005
2006 to 2008
2009 to 2011
Rural residence
Neighbourhood income quintile
1
2
3
4
5
Pharmacy forward sortation areac
Co-morbid conditionsd
Abdominal aortic aneurysm repair
Atrial fibrillation or flutter
Cerebrovascular disease

6346

Number of patients, n (%)a
AKI stageb
1
2
6012
290

3
44

69 (14)
70 (58-79)
2326 (36.7)
2475 (39.0)
1545 (24.3)
2948 (46.5)

69 (13)
70 (58-79)
2189 (36.4)
2351 (39.1)
1472 (24.5)
2745 (45.7)

68 (14)
70 (57-79)
112 (38.6)
114 (39.3)
64 (22.1)
177 (61.0)†

65 (13)‡§
62 (58-77)
25 (56.8)‡§
10 (22.7)‡§
9 (20.5)
26 (59.1)‡

1593 (25.1)
2903 (45.7)
1850 (29.2)
969 (15.3)

1497 (24.9)
2769 (46.1)
1746 (29.0)
912 (15.2)

87 (30.0)†
116 (40.0)†
87 (30.0)
51 (17.6)

9 (20.5)‡§
18 (40.9)‡
17 (38.6)‡§
6 (13.6)§

1401 (22.1)
1353 (21.3)
1307 (20.6)
1046 (16.5)
1140 (18.0)
5214 (82.2)

1314 (21.9)
1290 (21.5)
1238 (20.6)
996 (16.6)
1079 (17.9)
4945 (82.3)

78 (26.9)†
54 (18.6)
62 (21.4)
42 (14.5)
50 (17.2)
233 (80.3)

9 (20.5)§
9 (20.5)
7 (15.9)‡§
8 (18.2)§
11 (25.0)‡§
36 (81.8)

48 (0.8)
NR
NR

37 (0.8)
627 (10.4)
243 (4.0)

≤5 (≤1.7)
23 (7.9)
14 (4.8)

≤5 (≤11.4)‡
≤5 (≤11.4)‡
≤5 (≤11.4)‡§
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Chronic liver disease
Chronic obstructive pulmonary disease
Coronary artery diseasee
Dementia
Diabetes
Heart failure
Hypertension
Major cancerf
Nephrolithiasis
Osteoarthritis
Parkinson's disease
Peripheral vascular disease
Rheumatoid arthritis
Charlson co-morbidity indexg
0
1
2
≥3
Aggregated Diagnosis Groups scoreh
0-5
≥6
Medication utilizationi
ODB program eligible patients
Patients in long-term carej
Medication classk
Angiotensin-converting enzyme inhibitor or
angiotensin receptor blocker
Alpha-1-adrenoceptor antagonist or
5-alpha-reductase inhibitor

NR
NR
2160 (34.0)
NR
2405 (37.9)
NR
4783 (75.4)
1056 (16.6)
NR
NR
NR
NR
NR

399 (6.6)
369 (6.1)
2069 (34.4)
591 (9.8)
2292 (38.1)
1325 (22.0)
4525 (75.3)
994 (16.5)
162 (2.7)
431 (7.2)
32 (0.5)
178 (3.0)
429 (7.1)

24 (8.3)
22 (7.6)
78 (26.9)†
39 (13.4)†
100 (34.5)
48 (16.6)†
222 (76.6)
53 (18.3)
11(3.8)
26 (9.0)
≤5 (≤1.7)
≤5 (≤1.7)
22 (7.6)

≤5 (≤11.4)§
≤5 (≤11.4)‡§
13 (29.5)‡
≤5 (≤11.4)‡§
13 (29.5)‡§
≤5 (≤11.4)‡§
36 (81.8)‡§
9 (20.5)‡
≤5 (≤11.4)‡§
≤5 (≤11.4)‡§
≤5 (≤11.4)‡§
≤5 (≤11.4)
≤5 (≤11.4)

4181 (65.9)
NR
NR
824 (13.0)

3962 (65.9)
661 (11.0)
606 (10.1)
783 (13.0)

188 (64.8)
33 (11.4)
35 (12.1)
34 (11.7)

31 (70.5)§
≤5 (≤11.4)
≤5 (≤11.4)‡§
7 (15.9)§

1757 (27.7)
4589 (72.3)

1669 (27.8)
4343 (72.2)

79 (27.2)
211 (72.8)

9 (20.5)‡§
35 (79.5)‡§

4605 (72.6)
NR

4367 (72.6)
171/4367 (3.9)

213 (73.4)
13/213 (6.1)†

25 (56.8)‡§
≤5/25 (≤20.0)‡

2750/4605 (59.7)

2614/4367 (59.9)

122/213 (57.3)

14/25 (56.0)

NR

279/4367 (6.4)

13/213 (6.1)

≤5/25 (≤20.0)
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Anti-retroviral
Antibiotic
Anticoagulant
Antidepressant (SSRI or SNRI)
Antineoplastic (chemotherapy)
Antiplatelet
Antipsychotic
Beta-adrenergic antagonist
Calcium channel blocker
Corticosteroid
Immunosuppressive medication
Lithium
Non-potassium sparing diuretic
Non-steroidal anti-inflammatory drugl
Oral hypoglycemic agent or insulin
Potassium-sparing diuretic
Proton pump inhibitor
Statin
Xanthine oxidase inhibitor or uricosuric agent
Unique drug names
Mean (SD)
Median (IQR)
Unique drug identification numbers
Mean (SD)
Median (IQR)
Pre-ED visit baseline kidney functionm
Baseline SCr, in µmol/L
Mean (SD)
Median (IQR)
Days baseline SCr measured pre-ED visit

NR
2041/4605 (44.3)
NR
774/4605 (16.8)
NR
NR
NR
1781/4605 (38.7)
NR
1188/4605 (25.8)
NR
NR
2609/4605 (56.7)
892/4605 (19.4)
NR
NR
1651/4605 (35.9)
2174/4605 (47.2)
NR

7/4367 (0.2)
1931/4367 (44.2)
689/4367 (15.8)
728/4367 (16.7)
108/4367 (2.5)
714/4367 (16.3)
284/4367 (6.5)
1705/4367 (39.0)
1499/4367 (34.3)
1119/4367 (25.6)
166/4367 (3.8)
30/4367 (0.7)
2465/4367 (56.4)
849/4367 (19.4)
1346/4367 (30.8)
511/4367 (11.7)
1571/4367 (36.0)
2072/4367 (47.4)
302/4367 (6.9)

≤5/213 (≤2.3)
97/213 (45.5)
32/213 (15.0)
40/213 (18.8)
≤5/213 (≤2.3)
31/213 (14.6)
18/213 (8.5)
66/213 (31.0)†
64/213 (30.0)
63/213 (29.3)
13/213 (6.1)†
≤5/213 (≤2.3)†
128/213 (60.1)
34/213 (16.0)
52/213 (24.4)†
34/213 (16.0)†
68/213 (31.9)
93/213 (43.7)
≤5/213 (≤2.3)†

≤5/25 (≤20.0)
13/25 (52.0)‡§
≤5/25 (≤20.0)
6/25 (24.0)‡§
≤5/25 (≤20.0)‡§
≤5/25 (≤20.0)‡§
≤5/25 (≤20.0)
10/25 (40.0)§
≤5/25 (≤20.0)‡§
6/25 (24.0)§
≤5/25 ≤20.0)
≤5/25 ≤20.0)‡
16/25 (64.0)‡
9/25 (36.0)‡§
≤5/25 (≤20.0)‡§
≤5/25 (≤20.0)‡§
12/25 (48.0)‡§
9/25 (36.0)‡§
≤5/25 (≤20.0)‡§

6 (6)
5 (0-10)

6 (6)
5 (0-10)

6 (6)
5 (0-10)

3 (5)‡§
0 (0-7)

6 (6)
5 (0-10)

6 (6)
5 (0-10)

6 (7)
5 (0-10)

4 (6)‡§
0 (0-7)

101 (55)
87 (71-112)

102 (56)
88 (72-112)

76 (30)†
71 (56-87)

96 (88)§
75 (57-88)
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Mean (SD)
Median (IQR)
Baseline SCr ≤50 µmol/L
Baseline eGFR
≥60 ml/min/1.73m2
45 to <60 ml/min/1.73m2
30 to <45 ml/min/1.73m2
<30 ml/min/1.73m2
CKD risk categoryn
Low risk
Moderate risk
High risk
Very high risk
Urine ACR measured
<30 mg/mmol
30 to <300 mg/mmol
≥300 mg/mmol
ED visit laboratory values
Serum potassium, in mmol/L
Mean (SD)
Median (IQR)
Serum sodium, in mmol/L
Mean (SD)
Median (IQR)
SCr, in µmol/L
Mean (SD)
Median (IQR)
Absolute change in SCr, in µmol/L
Mean (SD)
Median (IQR)

133 (102)
106 (44-207)
NR

132 (102)
106 (44-206)
215 (3.6)

140 (105)
126 (45-215)
44 (15.2)†

152 (116)‡§
115 (46-256)
≤5 (≤11.4)‡§

3919 (61.8)
NR
NR
NR

3654 (60.8)
1029 (17.1)
833 (13.9)
496 (8.3)

230 (79.3)†
34 (11.7)†
19 (6.6)†
7 (2.4)†

35 (79.5)‡
≤5 (≤11.4)‡§
≤5 (≤11.4)‡
≤5 (≤11.4)§

NR
NR
NR
NR
1689 (26.6)
NR
NR
NR

678 (11.3)
293 (4.9)
366 (6.1)
654 (10.9)
1602 (26.6)
959 (16.0)
262 (4.4)
381 (6.3)

41 (14.1)
15 (5.2)
16 (5.5)
12 (4.1)†
77 (26.6)
49 (16.9)
13 (4.5)
15 (5.2)

≤5 (≤11.4)
≤5 (≤11.4)‡§
≤5 (≤11.4)
≤5 (≤11.4)§
10 (22.7)
≤5 (≤11.4)‡§
≤5 (≤11.4)
≤5 (≤11.4)

4.2 (0.6)
4.1 (3.8-4.5)

4.2 (0.6)
4.1 (3.8-4.5)

4.1 (0.8)†
4.1 (3.6-4.5)

4.2 (0.8)§
4.2 (3.6-4.8)

137 (5)
138 (135-140)

137 (5)
138 (135-140)

136 (5)†
137 (134-139)

134 (5)‡§
134 (131-139)

147 (70)
129 (109-162)

145 (66)
128 (108-159)

174 (75)†
159 (128-205)

335 (182)‡§
301 (200-427)

47 (31)
38 (31-51)

43 (19)
37 (31-48)

98 (46)†
88 (68-119)

239 (122)‡§
217 (139-328)
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Percent change in SCr, in %
Mean (SD)
Median (IQR)
Previous health care utilizationo
ED visit in the previous
30 days
31 to 365 days
Hospitalization in the previous
30 days
31 to 365 days
Outpatient physician visits
Family physician
0 to 4 visits
5 to 10 visits
≥11 visits
General internist (≥1 visit)
Nephrologist (≥1 visit)
Urologist (≥1 visit)
Diagnostic imaging and procedures
Abdominal ultrasoundp
Cardiac stress test
Coronary angiogram or
revascularization
CT scan with contrast
Echocardiogram
Intervention for kidney stonesq
ED and hospital characteristics
Institutionr
1

52 (34)
45 (35-60)

48 (18)
44 (34-57)

129 (26)†
121 (108-144)

294 (128)‡§
265 (224-359)

1114 (17.6)
2510 (39.5)

1062 (17.7)
2384 (39.7)

45 (15.5)
114 (39.3)

7 (15.9)
12 (27.3)‡§

481 (7.6)
1452 (22.9)

451 (7.5)
1366 (22.7)

24 (8.3)
78 (26.9)

6 (13.6)‡§
8 (18.2)‡§

6251 (98.5)
1069 (16.8)
2287 (36.0)
2990 (47.1)
1470 (23.2)
NR
1132 (17.8)

5924 (98.5)
1017 (16.9)
2161 (35.9)
2834 (47.1)
1385 (23.0)
270 (4.5)
1084 (18.0)

283 (97.6)
46 (15.9)
109 (37.6)
135 (46.6)
76 (26.2)
14 (4.8)
40 (13.8)†

44 (70.5)‡§
6 (13.6)
17 (38.6)
21 (47.7)
9 (20.5)§
≤5 (≤11.4)
8 (18.2)§

1530 (24.1)
NR
NR

1456 (24.2)
931 (15.5)
138 (2.3)

59 (20.3)
34 (11.7)†
6 (2.1)

15 (34.1)‡§
≤5 (≤11.4)‡§
≤5 (≤11.4)‡§

NR
NR
NR

175 (2.9)
1097 (18.2)
73 (1.2)

7 (2.4)
34 (11.7)†
≤5 (≤1.7)

≤5 (≤11.4)
≤5 (≤11.4)‡§
≤5 (≤11.4)

1754 (27.6)

1665 (27.7)

78 (26.9)

11 (25.0)
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2
3
4
5
6
7
8
9
10
11
12
13
ED and hospital activity
Standardized number of ED registrations
in the last 12hs
Mean (SD)
Median (IQR)
Standardized number of hospital admissions
in the last 24ht
Mean (SD)
Median (IQR)
Standardized number of hospital discharges
in the last 24hu
Mean (SD)
Median (IQR)
Standardized proportion of ED registrations
resulting in hospitalization, in %v
ED seasonal and time characteristics
Time of day
0700 to <1700

1482 (23.4)
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR

1400 (23.3)
608 (10.1)
435 (7.2)
145 (2.4)
42 (0.7)
569 (9.5)
241 (4.0)
338 (5.6)
366 (6.1)
148 (2.5)
32 (0.5)
23 (0.4)

70 (24.1)
36 (12.4)
26 (9.0)
10 (3.4)
≤5 (≤1.7)
35 (12.1)
7 (2.4)
10 (3.4)†
10 (3.4)†
≤5 (≤1.7)
≤5 (≤1.7)
≤5 (≤1.7)

12 (27.3)
≤5 (≤11.4)‡§
≤5 (≤11.4)
≤5 (≤11.4)‡
≤5 (≤11.4)‡§
≤5 (≤11.4)
≤5 (≤11.4)
≤5 (≤11.4)§
≤5 (≤11.4)
≤5 (≤11.4)‡§
≤5 (≤11.4)‡§
≤5 (≤11.4)

1.1 (0.3)
1.1 (0.9-1.3)

1.1 (0.3)
1.1 (0.9-1.3)

1.1 (0.3)
1.1 (0.9-1.3)

1.0 (0.3)‡§
1.0 (0.8-1.3)

1.1 (0.3)
1.1 (0.8-1.3)

1.1 (0.3)
1.1 (0.8-1.3)

1.1 (0.3)
1.1 (0.8-1.3)

1.1 (0.3)‡
1.2 (0.9-1.3)

1.1 (0.4)
1.1 (0.8-1.2)
47.0

1.1 (0.3)
1.1 (0.8-1.2)
47.0

1.1 (0.4)
1.1 (0.8-1.2)
49.0

1.1 (0.4)‡§
1.3 (0.9-1.4)
48.0

3320 (52.3)

3128 (52.0)

162 (55.9)

30 (71.1)‡§
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1700 to <2400
0000 to <0700
Seasonw
Fall
Winter
Spring
Summer
ED physician training
Emergency medicine
Family medicine
Other
ED patient acuity and wait times
CTASx
1 or 2
3
4 or 5
Time (in hours) waiting for physician
assessment, mean (SD)
CTAS 1 or 2
CTAS 3
CTAS 4 or 5
90% percentile ED length of stay, in hours
CTAS 1 or 2
CTAS 3
CTAS 4 or 5

2226 (35.1)
NR

2125 (35.3)
759 (12.6)

91 (31.4)
37 (12.8)

≥9 (≥20.5)‡§
≤5 (≤11.4)‡§

1502 (23.7)
1446 (22.8)
1635 (25.8)
1763 (27.8)

1418 (23.6)
1358 (22.6)
1563 (26.0)
1673 (27.8)

71 (24.5)
77 (26.6)
63 (21.7)†
79 (27.2)

13 (29.5)‡§
11 (25.0)
9 (20.5)‡
11 (25.0)

4642 (73.1)
1338 (21.1)
NR

4403 (73.2)
1264 (21.0)
345 (5.7)

210 (72.4)
62 (21.4)
18 (6.2)

29 (65.9)‡§
≥10 (≥22.7)‡§
≤5 (≤11.4)

1321 (20.8)
3797 (59.8)
1228 (19.4)

1271 (21.1)
3579 (59.5)
1162 (19.3)

43 (14.8)†
193 (66.6)†
54 (18.6)

7 (15.9)‡
25 (56.8)§
12 (27.3)‡§

0.6 (0.8)
1.3 (1.3)
1.6 (1.4)

0.6 (0.8)
1.3 (1.3)
1.6 (1.4)

0.5 (0.6)†
1.5 (1.3)
1.7 (1.4)

0.3 (0.5)‡§
1.6 (1.1)‡§
1.4 (1.2)‡§

9
9
8

9
9
8

10
8
9

7
10
8

Abbreviations: ACR, albumin-to-creatinine ratio; AKI, acute kidney injury; CKD, chronic kidney disease; CT, computed tomography; CTAS, Canadian Triage Acuity Scale; ED,
emergency department; eGFR, estimated glomerular filtration rate; IQR, interquartile range; ODB: Ontario Drug Benefit; NR, not reported; SCr, serum creatinine; SD, standard
deviation; SNRI, serotonin-norepinephrine reuptake inhibitors; SSRI, selective serotonin reuptake inhibitor.
A standardized difference of ≥10% was found between two AKI stage comparisons: † stage 1 vs. stage 2; ‡ stage 1 vs. stage 3; and § stage 2 vs. stage 3. To convert SCr from SI
units (µmol) to traditional units (mg/dL), divide by 88.42.

40

a

Numbers reported as n (%) unless otherwise noted. To comply with privacy regulations for minimizing the chance of patient re-identification, numbers of patients were
suppressed in the case of five or fewer patients. The total number of patients was not reported if there were other calculations that could result in the re-identification of five or
fewer patients.
b
Stage 1, evidence of a relative increase in SCr value of ≥50% to <100% or ≥26.5 µmol/L from baseline; stage 2, evidence of a relative increase in SCr value of ≥100% to <200%
from baseline; and stage 3, evidence of a relative increase in SCr value of >200% from baseline or an absolute increase in SCr value to ≥354 mg/dL or the initiation of dialysis.
c
Pharmacy forward sortation area refers to a region in Ontario represented by the first three letters of the postal code. This variable describes the number and proportion of
individuals who live in the same region as the pharmacy that provided them with prescription medications.
d
Look-back window for co-morbidities was five years unless otherwise noted.
e
Does not include angina.
f
Major cancers include the following tissues/organs: lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovaries, and esophagus.
g
Look-back window for the Charlson co-morbidity index was two years.63,64
h
The Aggregated Diagnosis Groups (ADG) point score, derived from the John Hopkins Adjusted Clinical Groups® system, score is a weighted measure of health care utilization
as a proxy measure for co-morbidity and accounts for the duration of condition, severity of condition, diagnostic certainty, etiology of the condition, and specialty care
involvement.65,66 The higher ADG score, the greater the co-morbidity. Individuals with an ADG score of 0 to 2 reflect low health care costs with no prior hospitalizations; ADG
score 3 to 5, high health care costs but no prior hospitalizations; ADG score 6 or more, high health care costs and at least one prior hospitalization.
i
Look-back window for medication utilization was 120 days.
j
Patients in long-term care were identified from the ODB database.
k
Percentages reported are based on the number of ODB program eligible patients (age 65 years and older).
l
Does not include acetylsalicylic acid.
m
Pre-ED visit look-back window was 7 to 365 days.
n
CKD risk categories derived from 2012 Kidney Diseases: Improving Global Outcomes guidelines. In addition to using urine ACR measurements, urine dipstick and protein
values were converted to an estimate urine ACR.67
o
Look-back window for health care utilization was 365 days unless otherwise noted.
p
An abdominal ultrasound is not specific for the assessment of the kidneys.
q
Urological procedures included extracorporeal shockwave lithotripsy, percutaneous nephrolithotomy, or ureteroscopic lithotripsy with stone removal.
r
For privacy considerations, individual hospital institutions were not identified.
s
Standardized to the mean number of ED registrations that occurred in the last 12-hour period over the last 14 days.
t
Standardized to the mean number of hospital admissions that occurred in the last 24-hour period over the last 14 days.
u
Standardized to the mean number of hospital discharges that occurred in the last 24-hour period over the last 14 days.
v
Proportion of registrations resulting in hospitalization standardized to each ED/hospital institution’s number of ED registrations occurring in the last 24 hours.
w
Fall: September 21 to December 20; Winter: December 21 to March 20; Spring: March 21 to June 20; Summer: June 21 to September 20.
x
Patients with a Canadian Triage Acuity Scale (CTAS) of 1 or 2 need to be seen immediately 98% of the time or within 15 minutes 95% of the time, respectively. Patients with a
CTAS of 3 or 4 need to be seen within 30 minutes 90% of the time or 60 minutes 85% of the time, respectively. Patients with a CTAS of 5 need to be seen within 120 minutes
80% of the time.
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5.1.3

Outcomes

In the 30 days following an ED discharge home with AKI, 149 (2.3%) patients died, 22
(0.3%) received hospital-based acute dialysis, and 1032 (16.3%) required hospitalization.
In the outpatient setting, 4287 (67.6%) were seen by a physician (family physician,
general internist, nephrologist, or urologist), 1446 (22.8%) had a SCr test, and 12% had a
urine test for protein (Table 5-2). The median (IQR) 30-day health care cost was $1172
($661-$3020) dollars.
In the 30 days following an ED discharge home, 127 (2.1%) patients with stage 1, 15
(5.2%) with stage 2, and 7 (15.9%) with stage 3 AKI died. There were 956 (15.9%)
patients with stage 1, 62 (21.4%) with stage 2, and 14 (31.8%) with stage 3 AKI who
required hospitalization. In the outpatient setting, 4062 (67.6%) patients with stage 1, 197
(67.9%) with stage 2, and 28 (63.6%) with stage 3 AKI visited a physician and 1339
(22.8%) patients with stage 1, 89 (30.7%) with stage 2, and 18 (40.9%) with stage 3 AKI
had a SCr measurement. Mean and median health care costs appeared to increase with
AKI severity.

Table 5-2: Thirty-Day Outcomes of Patients Discharged Home from the Emergency Department with Acute Kidney Injury
Outcome
Primary Outcome
All-cause mortality
Secondary Outcome
Receipt of hospital-based acute
dialysis
Additional Outcomes
At least one hospitalization
At least one outpatient:
Physician clinic visitc
SCr test
Urine test for proteind
Total health care costse
Mean (SD)
Median (IQR)

All patients
(N=6346)

Number of patients, n (%)a
AKI stageb
1 (N=6012)
2 (N=290)

3 (N=44)

149 (2.3)

127 (2.1)

15 (5.2)

7 (15.9)

22 (0.3)

NR

≤5 (≤1.7)

≤5 (≤11.4)

1032 (16.3)

956 (15.9)

62 (21.4)

14 (31.8)

4287 (67.6)
1446 (22.8)
NR

4062 (67.6)
1339 (22.3)
713 (11.9)

197 (67.9)
89 (30.7)
41 (14.1)

28 (63.6)
18 (40.9)
≤5 (≤11.4)

$3522 ($7079)
$1172 ($661-3020)

$3499 ($7135)
$1164 ($657-2955)

$3856 ($6065)
$1342 ($749-4372)

$4429 ($5454)
$1748 ($699-6478)

Abbreviations: AKI, acute kidney injury; IQR, interquartile range; NR, not reported; SCr, serum creatinine; SD, standard deviation.
a
Reported as n (%) unless otherwise noted. To comply with privacy regulations for minimizing the chance of patient re-identification, numbers of patients were suppressed in the
case of five or fewer patients. The total number of patients was not reported if there were other calculations that could result in the re-identification of five or fewer patients.
b
AKI stage 1, evidence of a relative increase in SCr value of ≥50% to <100% or ≥26.5 µmol/L from baseline; stage 2, evidence of a relative increase in SCr value of ≥100% to
<200% from baseline; and stage 3, evidence of a relative increase in SCr value of >200% from baseline or an absolute increase in SCr value to ≥354 µmol/L or the initiation of
dialysis.14
c
Outpatient physician specialties included any one of: family medicine, internal medicine, nephrology, or urology.
d
Tests for urine protein included any one of: dipstick, protein, or ACR.
e
Reported in Canadian dollars, adjusted for inflation to 2013.
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5.2 Propensity Score Matching Analysis
5.2.1
5.2.1.1

AKI Subpopulation
Unmatched Cohort

Cohort selection for the AKI subpopulation is presented in Figure 5-2. Baseline
characteristics before and after matching are presented in Table 5-3.
Before matching, there were 14,463 patients who visited an ED and had evidence of AKI.
Among these patients, 6346 were discharged home and 8117 were admitted to hospital.
Patients discharged home from the ED with AKI as compared to those admitted to
hospital from the ED with AKI were younger (mean age 69 vs. 73 years) and more likely
to have a slightly more remote pre-ED visit baseline SCr measurement [mean (median)
133 (106) vs. 121 (90) days], a slightly lower pre-ED visit baseline SCr concentration
[mean (median) 101 (87) vs. 115 (96) µmol/L], and a previous urine ACR measurement
(26.6 vs. 22.1%). In the ED, they were more likely to have a slightly lower serum
potassium [mean (median) 4.2 (4.1) vs. 4.4 (4.3) mmol/L], slightly higher serum sodium
concentration [mean (median) 137 (138) vs. 136 (136) mmol/L], lower ED SCr
concentration [mean (median) 147 (129) vs. 208 (162) µmol/L], stage 1 AKI (94.7 vs.
78.9%), be assigned a less urgent triage acuity level (CTAS 3: 59.8 vs 52.4%, CTAS 4 or
5: 19.4 vs. 8.8%), and in patients assigned an urgent or emergent triage acuity level,
spend more time waiting for a physician assessment (CTAS 1 or 2: 0.8 vs. 0.6 hours,
CTAS 3: 1.3 vs. 1.2 hours).
These patients had fewer co-morbidities (coronary artery disease: 34.0 vs. 38.5%, CKD:
38.2 vs. 51.9%, diabetes: 37.9 vs. 43.1%, hypertension: 75.4 vs. 79.5%, major cancer:
16.6 vs. 21.4%, Charlson co-morbidity index of ≥3: 13.0 vs. 20.4%, and ADG point score
of ≥6: 72.3 vs. 76.7%), and were less likely to have universal drug coverage (72.6 vs.
83.1%), be prescribed non-potassium sparing diuretics (56.7 vs. 62.4%), have stage 2 or 3
AKI (5.3 vs. 21.1%), require hospitalization in the previous 365 days (30.5 vs. 43.3%), be
seen by a family physician ≥11 times in the past year (47.1 vs. 53.1%), be seen at least
once by a general internist (23.2 vs. 30.6%), be seen in the ED during daytime (52.3 vs.
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71.5%) and overnight hours (12.6 vs. 17.1%), and be assigned an emergent triage acuity
level (CTAS 1 or 2: 20.8 vs. 38.7%).
There was no difference in female sex, rural residence, income, abdominal aortic
aneurysm repair, cerebrovascular disease, chronic liver disease, coronary artery disease,
nephrolithiasis, osteoarthritis, Parkinson’s disease, peripheral vascular disease,
rheumatoid arthritis, use of all medications except non-potassium sparing diuretics,
proportion of patients with a pre-ED visit baseline SCr ≤50 µmol/L, at least one ED visit
in the previous 365 days, at least one family physician visit, at least one nephrologist
visit, at least one urologist visit, abdominal ultrasound, cardiac stress test, coronary
angiogram or revascularization, intervention for kidney stones, season of the year, and
two ED physician specialties (Emergency Medicine and Family Medicine).

5.2.1.2

Matched Cohort

A total of 4379 patients discharged from the ED with AKI were successfully matched to
4379 patients admitted to hospital from the ED with AKI (Table 5-3). The matched
cohort comprised of 4091 (93.4%) patients with stage 1, 244 (5.6%) with stage 2, and 44
(1.0%) with stage 3 AKI. The two groups were well-balanced and showed no meaningful
differences in 91 of 92 measured baseline characteristics (Appendix G). The ED serum
sodium was slightly higher in the group of ED discharges with AKI [mean (SD) 137 (5)
vs. 136 (6) mmol/L, standardized difference 22%, reference range for serum sodium: 135
to 145 mmol/L].
The mean (SD) age of the entire matched cohort was 71 (13) years and 46.5% were
women. The most common co-morbid conditions were hypertension (79.4%), diabetes
(39.2%), CKD (45.0%), coronary artery disease (37.1%), and heart failure (26.7%).
Among patients with universal drug coverage through the ODB program (79.2%), 5.2%
resided in a long-term care facility and a median of five medications were prescribed in
the 120 days prior to the index date. The most commonly prescribed medications were
angiotensin-converting enzyme inhibitor or angiotensin receptor blockers (59.7%), non-
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potassium sparing diuretics (59.2%), statins (45.4%), antibiotics (45.2%), beta-adrenergic
antagonists (39.9%), proton pump inhibitors (36.8%), and calcium channel blockers
(34.4%). A urine ACR was measured in 23.9% of patients in the previous 365 days. Most
patients did not have a prior ED visit (previous 30 days: 81.1%, 31 to 365 days: 60.2%)
or hospitalization (previous 30 days: 90.0%, 31 to 365 days: 73.2%). Nearly all patients
(98.3%) were seen by their family physician at least once in the previous 365 days. Prior
visits to the general internist (26.4%), nephrologist (4.9%), or urologist (17.4%) were less
common.
The mean (median) pre-ED visit baseline SCr concentration among both groups was
approximately 107 (91) µmol/L. The mean (median) ED serum potassium, sodium, and
creatinine concentration was approximately 4.3 (4.1) mmol/L, 137 (138) mmol/L, and
158 (139) µmol/L, respectively. Most patients were triaged to emergent or urgent acuity
levels (CTAS 1 or 2: 27.1%, CTAS 3: 59.9%).
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Figure 5-2: Cohort Selection for the AKI Subpopulation

Abbreviations: AKI, acute kidney injury; ED, emergency department; ICD, International Classification of Diseases;
SCr, serum creatinine.
a
Patients were excluded in order as listed.
b
We selected the most recent pre-ED visit baseline SCr measurement.
c
If an individual had more than one ED visit with AKI, we selected the first ED visit.

Table 5-3: Baseline Characteristics of Patients in the AKI Subpopulation Pre- and Post-Match
Variable

Demographics
Age, in years
Mean (SD)
Median (IQR)
40 to <65
65 to <80
≥80
Sex, female
Year of cohort entry
2003 to 2005
2006 to 2008
2009 to 2011
Rural residence
Neighbourhood income
quintile
1
2
3
4
5
Pharmacy forward sortation
areab

Unmatched
Patient in the ED with AKIa
Discharged
Admitted to
home
hospital
(N = 6346)
(N= 8117)

Standardized
difference
(%)

69 (13)
70 (58-79)
2326 (36.7)
2475 (39.0)
1545 (24.3)
2948 (46.5)

73 (13)
75 (64-83)
2055 (25.3)
3178 (39.2)
2884 (35.5)
3737 (46.0)

32

1593 (25.1)
2903 (45.7)
1850 (29.2)
969 (15.3)
1401 (22.1)
1353 (21.3)
1307 (20.6)
1046 (16.5)
1140 (18.0)
5214 (82.2)

Matched
Patient in the ED with AKIa
Discharged
Admitted to
home
hospital
(N= 4379)
(N= 4379)

Standardized
difference
(%)

71 (13)
74 (62-81)
1298 (29.6)
1681 (38.4)
1400 (32.0)
2037 (46.5)

2

25
0
25
1

71 (13)
73 (62-81)
1267 (28.9)
1819 (41.5)
1293 (29.5)
2037 (46.5)

1999 (24.6)
3189 (39.3)
2929 (36.1)
1302 (16.0)

1
13
15
2

1114 (25.4)
1881 (43.0)
1384 (31.6)
685 (15.6)

1117 (25.5)
1911 (43.6)
1351 (30.9)
652 (14.9)

0
1
2
2

1892 (23.3)
1748 (21.5)
1608 (19.8)
1342 (16.5)
1391 (17.1)
6513 (80.2)

3
1
2
0
2
5

971 (22.2)
942 (21.5)
978 (22.3)
731 (16.7)
757 (17.3)
3562 (81.3)

989 (22.6)
932 (21.3)
957 (21.9)
732 (16.7)
769 (17.6)
3573 (81.6)

1
1
1
0
1
1

2
6
5
0

Co-morbid conditionsc
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Abdominal aortic aneurysm
repair
Atrial fibrillation or flutter
Cerebrovascular disease
Chronic liver disease
Chronic obstructive
pulmonary
disease
Coronary artery diseased
Dementia
Diabetes
Heart failure
Hypertension
Major cancere
Nephrolithiasis
Osteoarthritis
Parkinson's disease
Peripheral vascular disease
Rheumatoid arthritis
Charlson co-morbidity indexf
0
1
2
≥3
Aggregated Diagnosis
Groups scoreg
0-5
≥6

NR

78 (1.0)

2

38 (0.9)

38 (0.9)

0

NR
NR
NR
NR

1133 (14.0)
396 (4.9)
722 (8.9)
907 (11.2)

11
4
8
18

539 (12.3)
221 (5.0)
327 (7.5)
352 (8.0)

547 (12.5)
208 (4.7)
325 (7.4)
364 (8.3)

1
1
0
1

2160 (34.0)
NR
2405 (37.9)
NR
4783 (75.4)
1056 (16.6)
NR
NR
NR
NR
NR

3124 (38.5)
1204 (14.8)
3496 (43.1)
2591 (31.9)
6454 (79.5)
1735 (21.4)
191 (2.4)
631 (7.8)
82 (1.0)
371 (4.6)
604 (7.4)

9
15
11
23
10
12
2
2
5
9
1

1614 (36.9)
531 (12.1)
1728 (39.5)
1168 (26.7)
3475 (79.4)
829 (18.9)
117 (2.7)
344 (7.9)
32 (0.7)
154 (3.5)
317 (7.2)

1636 (37.4)
540 (12.3)
1703 (38.9)
1170 (26.7)
3475 (79.4)
843 (19.3)
110 (2.5)
330 (7.5)
32 (0.7)
156 (3.6)
309 (7.1)

1
1
1
0
0
1
1
1
0
0
1

4181 (65.9)
NR
NR
824 (13.0)

4338 (53.4)
1017 (12.5)
1110 (13.7)
1652 (20.4)

26
5
11
20

2676 (61.1)
515 (11.8)
489 (11.2)
699 (16.0)

2574 (58.8)
541 (12.4)
575 (13.1)
689 (15.7)

5
2
6
1

1757 (27.7)
4589 (72.3)

1892 (23.3)
6225 (76.7)

10
10

1124 (25.7)
3255 (74.3)

1114 (25.4)
3265 (74.6)

1
1

Medication utilizationh
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ODB program eligible
Patients in long-term carei
Medication classj
Alpha-1-adrenoceptor
antagonist or 5-alphareductase inhibitor
Angiotensin-converting
enzyme inhibitor or
angiotensin receptor
blocker
Anti-retroviral
Antibiotic
Anticoagulant
Antidepressant
(SSRI or SNRI)
Antineoplastic
(chemotherapy)
Antiplatelet
Antipsychotic
Beta-adrenergic antagonist
Calcium channel blocker
Corticosteroid
Immunosuppressive
medication
Lithium
Non-potassium sparing
diuretic
Non-steroidal antiinflammatory drugk
Oral hypoglycemic agent
or insulin

4605 (72.6)
NR

6748 (83.1)
458 (5.6)

26
12

3459 (79.0)
172 (5.0)

3477 (79.4)
188 (5.4)

1
2

NR

439 (6.5)

0

217 (6.3)

211 (6.1)

1

2750 (59.7)

4026 (59.7)

0

2065 (59.7)

2074 (59.6)

0

NR
2041 (44.3)
NR
774 (16.8)

12 (0.2)
3214 (47.6)
1253 (18.6)
1151 (17.1)

0
7
7
1

6 (0.2)
1567 (45.3)
594 (17.2)
566 (16.4)

≤5 (≤0.1)
1569 (45.1)
609 (17.5)
563 (16.2)

6
0
1
0

NR

150 (2.2)

2

83 (2.4)

82 (2.4)

0

NR
NR
1781 (38.7)
NR
1188 (25.8)
NR

1028 (15.2)
497 (7.4)
2712 (40.2)
2357 (34.9)
1904 (28.2)
291 (4.3)

3
3
3
2
5
2

557 (16.1)
226 (6.5)
1385 (40.0)
1193 (34.5)
935 (27.0)
144 (4.2)

558 (16.0)
228 (6.6)
1381 (39.7)
1196 (34.4)
943 (27.1)
127 (3.7)

0
0
1
0
0
3

NR
2609 (56.7)

45 (0.7)
4213 (62.4)

0
12

23 (0.7)
2034 (58.8)

21 (0.6)
2071 (59.6)

1
2

892 (19.4)

1245 (18.4)

2

660 (19.1)

657 (18.9)

0

NR

2069 (30.7)

0

1039 (30.0)

1016 (29.2)
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Potassium-sparing diuretic
Proton pump inhibitor
Statin
Xanthine oxidase inhibitor
or uricosuric agent
Unique drug names
Mean (SD)
Median (IQR)
Unique drug identification
numbers
Mean (SD)
Median (IQR)
Pre-ED visit baseline kidney
functionl
Baseline SCr, in µmol/L
Mean (SD)
Median (IQR)
Days baseline SCr measured
pre-ED visit
Mean (SD)
Median (IQR)
Baseline SCr ≤50 µmol/L
Baseline eGFR
≥60 ml/min/1.73m2
45 to <60 ml/min/1.73m2
30 to <45 ml/min/1.73m2
<30 ml/min/1.73m2
CKD risk categorym
Low risk

NR
1651 (35.9)
2174 (47.2)
NR

1013 (15.0)
2563 (38.0)
2932 (43.4)
576 (8.5)

9
4
8
7

445 (12.9)
1260 (36.4)
1584 (45.8)
245 (7.1)

481 (13.8)
1289 (37.1)
1563 (45.0)
262 (7.5)

3
1
2
2

6 (6)
5 (0-10)

7 (5)
6 (0-10)

27

6 (6)
6 (0-10)

6 (6)
6 (0-10)

1

6 (6)
5 (0-10)

8 (7)
7 (0-11)

27

7 (6)
6 (0-11)

7 (6)
6 (0-11)

2

101 (55)
87 (71-112)

115 (69)
96 (76-130)

23

106 (57)
90 (74-118)

107 (59)
91 (73-120)

2

133 (102)
106 (44-207)
NR

121 (99)
90 (36-188)
277 (3.4)

12

128 (101)
100 (40-203)
165 (3.8)

1

4

127 (101)
98 (41-197)
164 (3.7)

3919 (61.8)
NR
NR
NR

3907 (48.1)
1610 (19.8)
1470 (18.1)
1130 (13.9)

28
8
13
19

2435 (55.6)
815 (18.6)
695 (15.9)
434 (9.9)

2386 (54.5)
834 (19.0)
685 (15.6)
474 (10.8)

2
1
1
3

NR

558 (6.9)

16

422 (9.6)

352 (8.0)

6

1
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Moderate risk
High risk
Very high risk
Urine ACR measured
<3 mg/mmol
3 to <30 mg/mmol
≥30 mg/mmol
ED visit laboratory
characteristics
Serum potassium, in mmol/L
Mean (SD)
Median (IQR)
Serum sodium, in mmol/L
Mean (SD)
Median (IQR)
SCr, in µmol/L
Mean (SD)
Median (IQR)
AKI severity
Stage 1
Stage 2
Stage 3
Previous health care
utilizationn
ED visits in the previous
30 days
31 to 365 days
Hospitalizations in the

NR
NR
NR
1689 (26.6)
NR
NR
NR

382 (4.7)
394 (4.9)
1358 (16.7)
1794 (22.1)
1014 (12.5)
363 (4.5)
417 (5.1)

1
5
18
11
10
1
5

201 (4.6)
248 (5.7)
551 (12.6)
1078 (24.6)
633 (14.5)
186 (4.2)
259 (5.9)

208 (4.7)
236 (5.4)
586 (13.4)
1019 (23.3)
567 (12.9)
208 (4.7)
244 (5.6)

1
1
2
3
4
2
1

4.2 (0.6)
4.1 (3.8-4.5)

4.4 (0.9)
4.3 (3.8-4.9)

31

4.2 (0.6)
4.1 (3.8-4.5)

4.3 (0.8)
4.1 (3.7-4.7)

7

137 (5)
138 (135-140)

136 (7)
136 (133-139)

25

137 (5)
138 (135-140)

136 (6)
137 (134-139)

22

147 (70)
129 (109-162)

208 (158)
162 (124-230)

50

156 (74)
136 (113-174)

158 (73)
139 (114-178)

3

6012 (94.7)
290 (4.6)
44 (0.7)

6407 (78.9)
1007 (12.4)
703 (8.7)

48
28
38

4091 (93.4)
244 (5.6)
44 (1.0)

4091 (93.4)
244 (5.6)
44 (1.0)

0
0
0

1114 (17.6)
2510 (39.5)

1638 (20.2)
3252 (40.1)

7
1

818 (18.7)
1744 (39.8)

840 (19.2)
1743 (39.8)

1
0
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previous
30 days
31 to 365 days
Outpatient physician visits
Family physician
0 to 4 visits
5 to 10 visits
≥11 visits
General internist (≥1 visit)
Nephrologist (≥1 visit)
Urologist (≥1 visit)
Diagnostic imaging and
procedures
Abdominal ultrasoundo
Cardiac stress test
Coronary angiogram or
revascularization
CT scan with contrast
Echocardiogram
Intervention for kidney
stonesp
ED and hospital
characteristics
Institutionq
1
2
3
4
5

481 (7.6)
1452 (22.9)

1130 (13.9)
2387 (29.4)

21
15

419 (9.6)
1102 (25.2)

454 (10.4)
1245 (28.4)

3
7

6251 (98.5)
1069 (16.8)
2287 (36.0)
2990 (47.1)
1470 (23.2)
NR
1132 (17.8)

7965 (98.1)
1239 (15.3)
2571 (31.7)
4307 (53.1)
2486 (30.6)
496 (6.1)
1390 (17.1)

3
4
9
12
17
7
2

4319 (98.6)
646 (14.8)
1521 (34.7)
2212 (50.5)
1143 (26.1)
226 (5.2)
791 (18.1)

4294 (98.1)
732 (16.7)
1429 (32.6)
2218 (50.7)
1171 (26.7)
204 (4.7)
729 (16.6)

4
5
4
0
1
2
4

1530 (24.1)
NR
NR

2210 (27.2)
1056 (13.0)
157 (1.9)

7
6
2

883 (20.2)
619 (14.1)
91 (2.1)

886 (20.2)
627 (14.3)
102 (2.3)

0
0
2

NR
NR
NR

407 (5.0)
1820 (22.4)
96 (1.2)

11
11
0

157 (3.6)
1080 (24.7)
50 (1.1)

158 (3.6)
1083 (24.7)
50 (1.1)

0
0
1

1754 (27.6)
1482 (23.4)
NR
NR
NR

2565 (31.6)
2051 (25.3)
806 (9.9)
74 (0.9)
150 (1.8)

9
4
1
33
4

1336 (30.5)
1060 (24.2)
464 (10.6)
61 (1.4)
94 (2.1)

1317 (30.1)
1089 (24.9)
472 (10.8)
62 (1.4)
107 (2.4)

1
2
1
0
2
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6
7
8
9
10
11
12
13
ED and hospital activity
Standardized number of
ED registrations in the
last 12hr
Mean (SD)
Median (IQR)
Standardized number of
hospital admissions
in the last 24hs
Mean (SD)
Median (IQR)
Standardized number of
hospital inpatient
discharges in the last 24ht
Mean (SD)
Median (IQR)
Standardized number of
ED registrations resulting
in hospitalization, in %u
ED seasonal and time
characteristics
Time of day

NR
NR
NR
NR
NR
NR
NR
NR

70 (0.9)
833 (10.3)
332 (4.1)
369 (4.5)
657 (8.1)
139 (1.7)
39 (0.5)
32 (0.4)

2
2
1
5
8
5
1
1

36 (0.8)
466 (10.6)
180 (4.1)
246 (5.6)
308 (7.0)
88 (2.0)
22 (0.5)
18 (0.4)

31 (0.7)
447 (10.2)
186 (4.2)
242 (5.5)
295 (6.7)
90 (2.1)
23 (0.5)
18 (0.4)

1
1
1
0
1
0
0
0

1.1 (0.3)
1.1 (0.9-1.3)

1.1 (0.3)
1.1 (0.9-1.3)

14

1.1 (0.3)
1.9 (0.9-1.3)

1.1 (0.3)
1.9 (0.9-1.3)

0

1.1 (0.3)
1.1 (0.8-1.3)

1.1 (0.3)
1.1 (0.8-1.3)

3

1.1 (0.3)
1.1 (0.8-1.3)

1.1 (0.3)
1.1 (0.8-1.3)

0

1.1 (0.4)
1.1 (0.8-1.2)
47.0

1.1 (0.4)
1.1 (0.8-1.3)
51.0

3

1.1 (0.3)
1.1 (0.8-1.3)
49.5

1.1 (0.4)
1.1 (0.8-1.3)
49.3

3

8

0
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0700 to <1700
1700 to <2400
0000 to <0700
Seasonv
Fall
Winter
Spring
Summer
ED physician training
Emergency medicine
Family medicine
Other
ED patient acuity and wait
times
CTASw
1 or 2
3
4 or 5
Time (hours) waiting for
physician assessment, mean
(SD)
CTAS 1 or 2
CTAS 3
CTAS 4 or 5

3320 (52.3)
2226 (35.1)
800 (12.6)

4538 (71.5)
2495 (39.3)
1084 (17.1)

40
9
13

2298 (52.5)
1497 (34.2)
584 (13.3)

2381 (54.4)
1423 (32.5)
575 (13.1)

4
4
1

1502 (23.7)
1446 (22.8)
1635 (25.8)
1763 (27.8)

2141 (26.4)
1925 (23.7)
1959 (24.1)
2092 (25.8)

6
2
4
5

1067 (24.4)
1033 (23.6)
1108 (25.3)
1171 (26.7)

1105 (25.2)
1013 (23.1)
1086 (24.8)
1175 (26.8)

2
1
1
0

4642 (73.1)
1338 (21.1)
NR

5781 (71.2)
1602 (19.7)
734 (9.0)

4
3
13

3140 (71.7)
945 (21.6)
294 (6.7)

3152 (72.0)
936 (21.4)
291 (6.6)

1
1
0

1321 (20.8)
3797 (59.8)
1228 (19.4)

3142 (38.7)
4257 (52.4)
718 (8.8)

40
15
31

1192 (27.2)
2620 (59.8)
567 (12.9)

1185 (27.1)
2626 (60.0)
568 (13.0)

0
0
0

0.6 (0.8)
1.3 (1.3)
1.6 (1.4)

0.5 (0.8)
1.2 (1.2)
1.7 (1.7)

16
12
2

0.6 (0.8)
1.3 (1.1)
1.4 (1.3)

0.5 (0.6)
1.2 (1.2)
1.6 (1.6)

7
3
9

Abbreviations: ACR, albumin-to-creatinine ratio; AKI, acute kidney injury; CKD, chronic kidney disease; CT, computed tomography; CTAS, Canadian Triage Acuity Scale; ED,
emergency department; eGFR, estimated glomerular filtration rate; IQR, interquartile range; ODB, Ontario Drug Benefit; NR, not reported; SD, standard deviation; SCr, serum
creatinine; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
To convert SCr from SI units (µmol/L) to traditional units (mg/dL), divide by 88.42.
a
Data reported as n (%) unless otherwise noted. To comply with privacy regulations for minimizing the chance of patient re-identification, numbers of patients were suppressed in
the case of five or fewer patients. The total number of patients was not reported if there were other calculations that could result in the re-identification of five or fewer patients.
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b

Pharmacy forward sortation area refers to a region in Ontario represented by the first three letters of the postal code. This variable describes the number and proportion of
individuals who live in the same region as the pharmacy that provided them with prescription medications.
c
Look-back window for co-morbidities was five years unless otherwise noted.
d
Does not include angina.
e
Major cancers include the following tissues/organs: lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovaries, and esophagus.
f
Look-back window for the Charlson co-morbidity index was two years.63,64
g
The Aggregated Diagnosis Groups (ADG) point score, derived from the John Hopkins Adjusted Clinical Groups® system, score is a weighted measure of health care utilization
as a proxy measure for co-morbidity and accounts for the duration of condition, severity of condition, diagnostic certainty, etiology of the condition, and specialty care
involvement.65,66 The higher ADG score, the greater the co-morbidity. Individuals with an ADG score of 0 to 2 reflect low health care costs with no prior hospitalizations; ADG
score 3 to 5, high health care costs but no prior hospitalizations; ADG score 6 or more, high health care costs and at least one prior hospitalization.
h
Look-back window for medication utilization was 120 days.
i
Patients in long-term care were identified from the ODB database.
j
Percentages reported are based on the number of ODB program eligible patients (age 65 years and older).
k
Does not includes acetylsalicylic acid.
l
Pre-ED look-back window was 7 to 365 days.
m
CKD risk categories derived from the 2012 Kidney Diseases: Improving Global Outcomes consensus guidelines. In addition to using urine ACR measurements, urine dipstick
and protein values were converted to an estimate urine ACR.67
n
Look-back window for health care utilization was 365 days unless otherwise noted.
o
Not specific for the assessment of the kidneys.
p
Urological procedures included extracorporeal shockwave lithotripsy, percutaneous nephrolithotomy, or ureteroscopic lithotripsy with stone removal.
q
For privacy considerations, individual hospital institutions were not identified.
r
Standardized to the mean number of ED registrations that occurred in the last 12-hour period over the last 14 days.
s
Standardized to the mean number of hospital admissions that occurred in the last 24-hour period over the last 14 days.
t
Standardized to the mean number of hospital discharges that occurred in the last 24-hour period over the last 14 days.
u
Proportion of registrations resulting in hospitalization standardized to each ED/hospital institution’s number of ED registrations occurring in the last 24 hours.
v
Fall: September 21 to December 20; Winter: December 21 to March 20; Spring: March 21 to June 20; Summer: June 21 to September 20.
w
Patients with a CTAS of 1 or 2 need to be seen immediately 98% of the time or within 15 minutes 95% of the time, respectively. Patients with a CTAS of 3 or 4 need to be seen
within 30 minutes 90% of the time or 60 minutes 85% of the time, respectively. Patients with a CTAS of 5 need to be seen within 120 minutes 80% of the time.
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5.2.1.3

Outcomes

The primary and secondary outcome for the AKI subpopulation is shown in Table 5-4. In
the 30-day follow-up period across the entire cohort, 652 (7.4%) patients died and 52
(0.6%) received hospital-based acute dialysis.
Compared to patients admitted to hospital from the ED with AKI, fewer patients
discharged home from the ED with AKI died within 30 days of the index date [130
(3.0%) vs. 522 (11.9%), RR: 0.25, 95% CI: 0.21-0.30, P<0.001]. Fewer patients
discharged home from the ED with AKI received hospital-based acute dialysis within 30
days of the index date, although the difference did not reach statistical significance [19
(0.43%) vs. 33 (0.75%), RR: 0.57, 95% CI: 0.33 to 1.01, P=0.06].

5.2.1.4

Subgroup Analysis

A subgroup analysis for all-cause mortality by AKI stage is shown in Table 5-5. The
relative association between an ED discharge and the risk of all-cause mortality was
attenuated with more severe forms of AKI [stage 1 RR (95% CI): 0.23 (0.18-0.29), stage
2: 0.40 (0.22-0.69), and stage 3: 1.00 (0.38-2.64); P value for interaction <0.001)].
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Table 5-4: Thirty-Day Risk of All-Cause Mortality and Need for Hospital-Based Acute
Dialysis in a Matched Cohort of Patients in the AKI Subpopulation

Outcome
All-cause mortality
Receipt of hospitalbased acute dialysis

ED patient events, n (%)
Discharged
Admitted to
home with
hospital with
AKI
AKI
(N = 4379)
(N = 4379)
130 (3.0)
522 (11.9)
19 (0.4)

33 (0.8)

Relative riska
(95% CI)

P value

0.25 (0.21-0.30)

<0.001

0.57 (0.33-1.01)

0.06

Abbreviations: AKI, acute kidney injury; CI, confidence interval; ED, emergency department.
a
Patients admitted to hospital from the ED with AKI served as the referent group.
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Table 5-5: The Association Between Emergency Department Disposition and 30-Day
All-Cause Mortality in the AKI Subpopulation Examined in a Subgroup Defined by
Acute Kidney Injury Stage
AKI stage
1
2
3

ED patient events, n/N (%)a
Discharged
Admitted to
home with AKI hospital with AKI
108/4091 (2.6)
477/4091 (11.7)
15/244 (6.1)
38/244 (15.6)
7/44 (15.9)
7/44 (15.9)

Relative riskb
(95% CI)
0.23 (0.18-0.28)
0.40 (0.22-0.69)
1.00 (0.38-2.64)

Abbreviations: AKI, acute kidney injury; CI, confidence interval; ED, emergency department.
a
n = number of events, N = number at risk.
b
Patients admitted to hospital from the ED with AKI served as the referent group.

Interaction
P value
<0.001
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5.2.2
5.2.2.1

Discharged Subpopulation
Unmatched Cohort

Cohort selection for the AKI subpopulation is presented in Figure 5-3. Baseline
characteristics before and after matching are presented in Table 5-6.
Before matching, there were 49,768 patients who visited an ED and were discharged
home. Among these patients, 6346 had AKI and 43,422 did not have AKI. ED patients
discharged home with AKI as compared to those with no AKI were older (mean age 69
vs. 63 years) and more likely to have coronary artery disease (34.0 vs. 20.0%), CKD
(38.2 vs. 17.3%), diabetes (37.9 vs. 24.6%), hypertension (75.4 vs. 59.2%), a Charlson
co-morbidity index of ≥3: 13.0 vs. 4.5%, an ADG score of ≥6: 72.3 vs. 59.5%, universal
drug coverage (72.6 vs. 52.6%), be prescribed a greater number of medications (median 6
vs. 3) in the previous 120 days such as angiotensin-converting enzyme inhibitors or
angiotensin II receptor blockers, antibiotics, beta-adrenergic antagonists, non-potassium
sparing medications, oral hypoglycemic agents or insulin, proton pump inhibitors, and
statins, have a higher pre-ED visit baseline SCr concentration [mean (median) 101 (87)
vs. 81 (76) µmol/L], have a previous abdominal ultrasound (24.1 vs. 19.1%), a prior ED
visit (previous 30 days: 17.6 vs. 8.6%; 31 to 365 days: 39.5 vs. 32.0%) or hospitalization
(previous 31 to 365 days: 22.9 vs. 13.7%), be seen by a family physician ≥11 times in the
past year (47.1 vs. 31.1%), and be seen at least once by a urologist (17.8 vs. 11.7%).
These patients were more likely to visit the ED in the evening (35.1 vs. 27.8%), have a
higher ED serum potassium concentration [mean (median) 4.2 (4.1) vs. 4.0 (3.9)
mmol/L], and have a lower ED serum sodium concentration [mean (median) 137 (138)
vs. 138 (139) mmol/L].
ED patients discharged home with AKI as compared to those with no AKI were less
likely to be female (46.5 vs. 56.5%), have an eGFR ≥60 mL/min/1.73m2 (61.8 vs.
82.7%), and visit an ED during daytime hours (52.3 vs. 57.6%).
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There was no difference in rural residence, income, abdominal aortic aneurysm repair,
chronic liver disease, major cancer, nephrolithiasis, osteoarthritis, Parkinson’s disease,
and rheumatoid arthritis, use of alpha-one-adrenoceptor antagonists or five-alphareductase inhibitors, anti-retrovirals, antidepressants, antineoplastics, antipsychotics,
corticosteroids, immunosuppression, lithium, or non-steroidal anti-inflammatory drugs,
number of days the pre-ED visit baseline SCr was measured prior to the index date,
proportion of patients with pre-ED visit baseline SCr ≤50 µmol/L, proportion of patients
with a pre-ED visit urine ACR measurement, hospitalization in the previous 30 days, at
least one family physician visit, at least one general internist visit, cardiac stress test,
coronary angiogram or revascularization, intervention for kidney stones, season of the
year, CTAS, time waiting for a physician assessment, any ED physician specialty, and
90th percentile for ED length of stay.

5.2.2.2

Matched Cohort

A total of 6188 patients discharged home from the ED with AKI were successfully
matched to 6188 patients discharged home from the ED with no AKI (Table 5-6). The
matched cohort comprised of 3904 (63.1%) patients with an eGFR ≥60, 1054 (17.0%)
with an eGFR 45 to <60, 803 (13.0%) with an eGFR 30 to <45, and 427 (6.9%) with an
eGFR <30 mL/min/1.73m2. The two groups were well-balanced and showed no
meaningful differences in 89 of 91 measured baseline characteristics (Appendix G). The
group discharged home from the ED with AKI had a higher mean (SD) ED serum
potassium concentration [4.2 (0.6) vs. 4.0 (0.5) mmol/L, standardized difference 21%,
reference range: 3.5 to 5.0 mmol/L] and was more likely to visit an ED in the previous 30
days (17.1 vs. 13.5%, standardized difference 10.1%).
The mean (SD) age of the entire matched cohort was 69 (14) years and 47.2% were
women. The most common co-morbid conditions were hypertension (75.1%), diabetes
(37.2%), CKD (36.9%), coronary artery disease (33.2%), and heart failure (20.2%). In
patients with universal drug coverage through the ODB program (72.6%), 3.6% resided
in a long-term care facility and a median of five medications were prescribed in the 120
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days prior to the index date. The most commonly prescribed medications were
angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (59.2%), nonpotassium sparing diuretics (55.4%), statins (46.3%), antibiotics (43.7%), beta-adrenergic
antagonists (38.0%), proton pump inhibitors (34.9%), and calcium channel blockers
(32.9%). A urine ACR was measured in 26.2% of patients in the previous 365 days. Most
patients did not have a prior ED visit (previous 30 days: 84.7%, 31 to 365 days: 61.4%)
or hospitalization (previous 30 days: 92.8%, 31 to 365 days: 77.7%). Nearly all patients
(98.5%) were seen by their family physician at least once in the previous 365 days. Prior
visits to the general internist (22.8%), nephrologist (3.8%), and urologist (17.4%) were
less common.
The mean (median) pre-ED visit baseline SCr concentration was approximately 98 (87)
µmol/L. The mean (median) ED serum potassium and sodium concentration was
approximately 4.2 (4.0) mmol/L and 138 (139) mmol/L, respectively. Most patients were
triaged to emergent or urgent acuity levels (CTAS 1 or 2: 20.9%, CTAS 3: 58.1%). The
90th percentile for ED length of stay ranged between 8 and 9 hours.

5.2.2.3

Outcomes

The primary and secondary outcome for the discharged subpopulation is shown in Table
5-7. In the 30-day follow-up period across the entire cohort, 223 (3.6%) patients died and
26 (0.4%) received hospital-based acute dialysis.
Compared to patients discharged from the ED with no AKI, more patients discharged
home from the ED with AKI died [136 (2.2%) vs. 87 (1.4%), RR: 1.56, 95% CI: 1.20 to
2.04, P=0.001] and received hospital-based acute dialysis within 30 days of the index
date [19 (0.43%) vs. 7 (0.11%), RR: 2.71, 95% CI: 1.22 to 6.02, P=0.01].
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5.2.2.4

Subgroup Analysis

A subgroup analysis for all-cause mortality by CKD stage is shown in Table 5-8. The
association between AKI and the risk of all-cause mortality was not modified by CKD
stage (P value for interaction <0.57).
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Figure 5-3: Cohort Selection for the Discharged Subpopulation

Abbreviations: AKI, acute kidney injury; ED, emergency department; ICD, International Classification of Diseases;
SCr, serum creatinine.
a
Patients were excluded in order as listed.
b
We selected the most recent pre-ED visit baseline SCr measurement.
c
If an individual had more than one ED visit with AKI, we selected the first ED visit.
d
If an individual had more than one ED visit with no AKI, we selected the first ED visit. However, preference was
given to the group discharged home from the ED with AKI if patients were also eligible for this referent group.

Table 5-6: Baseline Characteristics of Patients in the Discharged Subpopulation Pre- and Post-Match
Variable
Demographics
Age, in years
Mean (SD)
Median (IQR)
40 to <65
65 to <80
≥80
Sex, female
Year of cohort entry
2003 to 2005
2006 to 2008
2009 to 2011
Rural residence
Neighbourhood income
quintile
1
2
3
4
5
Pharmacy forward sortation
areab
Co-morbid conditionsc
Abdominal aortic aneurysm

Unmatched
Discharged homea
AKI
No AKI
(N = 6346)
(N = 43422)

Standardized
difference
(%)

69 (13)
70 (58-79)
2326 (36.7)
2475 (39.0)
1545 (24.3)
2948 (46.5)

63 (14)
62 (51-74)
24036 (55.4)
13061 (30.1)
6325 (14.6)
24532 (56.5)

42

1593 (25.1)
2903 (45.7)
1850 (29.2)
969 (15.3)

Matched
Discharged homea
AKI
No AKI
(N = 6188)
(N = 6188)

Standardized
difference
(%)

69 (14)
71 (58-80)
2190 (35.4)
2429 (39.3)
1569 (25.4)
2940 (47.5)

2

38
19
25
20

68 (13)
70 (58-79)
2309 (37.3)
2401 (38.8)
1478 (23.9)
2900 (46.9)

8611 (19.8)
17056 (39.3)
17755 (40.9)
6299 (14.5)

13
13
25
2

1559 (25.2)
2811 (45.4)
1818 (29.4)
940 (15.2)

1558 (25.2)
2839 (45.9)
1791 (28.9)
957 (15.5)

0
1
1
1

1401 (22.1)
1353 (21.3)
1307 (20.6)
1046 (16.5)
1140 (18.0)

8814 (20.3)
9012 (20.8)
8757 (20.2)
7896 (18.2)
8520 (19.6)

4
1
1
4
4

1372 (22.2)
1306 (21.1)
1372 (22.2)
1023 (16.5)
1115 (18.0)

1416 (22.9)
1323 (21.4)
1330 (21.5)
999 (16.1)
1120 (18.1)

2
1
2
1
0

5214 (82.2)

34871 (80.3)

5

5089 (82.2)

5059 (81.8)

1

NR

162 (0.4)

5

47 (0.8)

55 (0.9)

1

4
1
3
1
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repair
Atrial fibrillation or flutter
Cerebrovascular disease
Chronic liver disease
Chronic obstructive pulmonary
disease
Coronary artery diseased
Dementia
Diabetes
Heart failure
Hypertension
Major cancere
Nephrolithiasis
Osteoarthritis
Parkinson's disease
Peripheral vascular disease
Rheumatoid arthritis
Charlson co-morbidity indexf
0
1
2
≥3
Aggregated Diagnosis Groups
scoreg
0-5
≥6
Medication utilizationh
ODB eligible
Patients in long-term

NR
NR
NR

1759 (4.1)
706 (1.6)
2203 (5.1)

24
15
7

606 (9.8)
234 (3.8)
412 (6.7)

581 (9.4)
230 (3.7)
392 (6.3)

1
0
1

NR

1140 (2.6)

17

359 (5.8)

337 (5.4)

2

2160 (34.0)
NR
2405 (37.9)
NR
4783 (75.4)
1056 (16.6)
NR
NR
NR
NR
NR

8678 (20.0)
2428 (5.6)
10678 (24.6)
3460 (8.0)
25725 (59.2)
5918 (13.6)
666 (1.5)
2580 (5.9)
114 (0.3)
1759 (4.1)
2595 (6.0)

32
16
29
39
35
8
8
5
4
13
5

2062 (33.3)
607 (9.8)
2294 (37.1)
1280 (20.7)
4630 (74.8)
1026 (16.6)
169 (2.7)
444 (7.2)
32 (0.5)
174 (2.8)
445 (7.2)

2049 (33.1)
614 (9.9)
2308 (37.3)
1226 (19.8)
4668 (75.4)
1016 (16.4)
170 (2.7)
434 (7.0)
38 (0.6)
163 (2.6)
437 (7.1)

0
0
0
2
1
0
0
1
1
1
1

4181 (65.9)
NR
NR
824 (13.0)

35911 (82.7)
2900 (6.7)
2657 (6.1)
1954 (4.5)

39
15
15
30

4139 (66.9)
683 (11.0)
618 (10.0)
748 (12.1)

4246 (68.6)
640 (10.3)
639 (10.3)
663 (10.7)

4
2
1
4

1757 (27.7)
4589 (72.3)

17586 (40.5)
25836 (59.5)

27
27

1738 (28.1)
4450 (71.9)

1777 (28.7)
4411 (71.3)

1
1

4605 (72.6)
NR

22849 (52.6)
441 (1.9)

42
12

3459 (79.0)
172 (3.9)

3477 (79.4)
188 (4.3)

3
2
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carei
Medication classj
Alpha-1-adrenoceptor
antagonist or 5-alphareductase inhibitor
Angiotensin-converting
enzyme inhibitor or
angiotensin receptor
blocker
Anti-retroviral
Antibiotic
Anticoagulant
Antidepressant
(SSRI or SNRI)
Antineoplastic
(chemotherapy)
Antiplatelet
Antipsychotic
Beta-adrenergic antagonist
Calcium channel blocker
Corticosteroid
Immunosuppressive
medication
Lithium
Non-potassium sparing
diuretic
Non-steroidal antiinflammatory drugk
Oral hypoglycemic agent or
insulin
Potassium-sparing

NR

1078 (4.7)

7

277 (6.2)

255 (5.6)

3

2750 (59.7)

10530 (46.1)

28

2644 (59.4)

2680 (59.1)

1

NR
2041 (44.3)
NR
774 (16.8)

40 (0.2)
8297 (36.3)
2287 (10.0)

0
16
17

7 (0.2)
1954 (43.9)
673 (15.1)

8 (0.2)
1972 (43.5)
646 (14.2)

0
1
2

3534 (15.5)

4

738 (16.6)

767 (16.9)

1

463 (2.0)

3

110 (2.5)

121 (2.7)

1

NR
NR
1781 (38.7)
NR
1188 (25.8)
NR

2442 (10.7)
1335 (5.8)
6467 (28.3)
5647 (24.7)
5280 (23.1)

16
3
22
21
6

705 (15.8)
286 (6.4)
1697 (38.1)
1488 (33.4)
1155 (25.9)

712 (15.7)
298 (6.6)
1716 (37.8)
1468 (32.4)
1172 (25.8)

0
1
1
2
0

784 (3.4)

3

175 (3.9)

184 (4.1)

1

NR
2609 (56.7)

171 (0.7)
8421 (36.9)

1
40

30 (0.7)
2476 (55.6)

30 (0.7)
2504 (55.2)

0
1

892 (19.4)

4347 (19.0)

1

871 (19.6)

894 (19.7)

0

4221 (18.5)

28

1320 (29.6)

1328 (29.3)

1

1431 (6.3)

20

512 (11.5)

505 (11.1)

1

NR

NR
NR
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diuretic
Proton pump inhibitor
Statin
Xanthine oxidase
inhibitor or uricosuric
agent
Unique drug names
Mean (SD)
Median (IQR)
Unique drug identification
numbers
Mean (SD)
Median (IQR)
Pre-ED visit baseline kidney
functionl
Baseline SCr, in µmol/L
Mean (SD)
Median (IQR)
Days baseline SCr
measured pre-ED visit
Mean (SD)
Median (IQR)
Baseline SCr ≤50 µmol/L
Baseline eGFR
≥60 ml/min/1.73m2
45 to <60 ml/min/1.73m2
30 to <45 ml/min/1.73m2
<30 ml/min/1.73m2
CKD risk categorym

1651 (35.9)
2174 (47.2)
NR

6878 (30.1)
9087 (39.8)
703 (3.1)

12
15
17

1588 (35.7)
2085 (46.8)
273 (6.1)

1548 (34.1)
2075 (45.8)
269 (5.9)

3
2
1

6 (6)
5 (0-10)

3 (4)
3 (0-9)

54

5 (5)
5 (0-9)

5 (5)
5 (0-9)

0

6 (6)
5 (0-10)

3 (5)
3 (0-10)

54

6 (6)
5 (0-10)

6 (6)
5 (0-10)

0

101 (55)
87 (71-112)

81 (28)
76 (65-90)

45

98 (50)
86 (71-109)

98 (49)
87 (71-110)

1

133 (102)
106 (44-207)
NR

137 (103)
114 (46-215)
1309 (3.0)

4

134 (103)
106 (43-210)
264 (4.3)

0

6

133 (102)
107 (45-209)
263 (4.3)

3919 (61.8)
NR
NR
NR

35924 (82.7)
4836 (11.1)
2022 (4.7)
640 (1.5)

48
16
31
31

3904 (63.1)
1054 (17.0)
803 (13.0)
427 (6.9)

3904 (63.1)
1054 (17.0)
803 (13.0)
427 (6.9)

0
0
0
0

0
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Low risk
Moderate risk
High risk
Very high risk
Urine ACR measured
<3mg/mmol
3 to <30 mg/mmol
≥30 mg/mmol

NR
NR
NR
NR
1689 (26.6)
NR
NR
NR

6393 (14.7)
1436 (3.3)
1910 (4.4)
988 (2.3)
10210 (23.5)
7404 (17.1)
978 (2.3)
1828 (4.2)

10
8
7
34
7
3
12
9

721 (11.7)
304 (4.9)
377 (6.1)
578 (9.3)
1648 (26.6)
999 (16.1)
267 (4.3)
382 (6.2)

679 (11.0)
296 (4.8)
391 (6.3)
570 (9.2)
1591 (25.7)
964 (15.6)
228 (3.7)
399 (6.4)

2
1
1
0
2
2
3
1

ED visit laboratory
characteristics
Serum potassium, in mmol/L
Mean (SD)
Median (IQR)
Serum sodium, in mmol/L
Mean (SD)
Median (IQR)

4.2 (0.6)
4.1 (3.8-4.5)

4.0 (0.5)
3.9 (3.7-4.2)

33

4.2 (0.6)
4.0 (3.8-4.5)

4.0 (0.5)
4.0 (3.7-4.3)

21

137 (5)
138 (135-140)

138 (4)
139 (137-141)

20

1114 (17.6)
2510 (39.5)

3745 (8.6)
13880 (32.0)

27
16

1061 (17.1)
2438 (39.4)

836 (13.5)
2335 (37.7)

10p
3

481 (7.6)
1452 (22.9)

2421 (5.6)
5928 (13.7)

8
24

460 (7.4)
1375 (22.2)

429 (6.9)
1390 (22.5)

2
1

6251 (98.5)
1069 (16.8)

42483 (97.8)
11584 (26.7)

5
24

6095 (98.5)
1058 (17.1)

6098 (98.5)
1072 (17.3)

0
1

Previous health care
utilizationo
ED visits in the previous
30 days
31 to 365 days
Hospitalizations in the
previous
30 days
31 to 365 days
Outpatient physician visits
Family physician
0 to 4 visits

138 (5)
138 (4)
138 (136-140) 139 (136-140)

10n
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5 to 10 visits
≥11 visits
General internist (≥1 visit)
Nephrologist (≥1 visit)
Urologist (≥1 visit)
Diagnostic imaging or
procedures
Abdominal ultrasoundq
Cardiac stress test
Coronary angiogram or
revascularization
CT with contrast
Echocardiogram
Intervention for kidney
stonesr
ED and hospital
characteristics
Institutions
1
2
3
4
5
6
7
8
9
10
11

2287 (36.1)
2990 (47.1)
1470 (23.2)
NR
1132 (17.8)

18323 (42.2)
13515 (31.1)
6619 (15.2)
561 (1.3)
5085 (11.7)

13
33
4
29
40

2258 (36.5)
2872 (46.4)
1407 (22.7)
260 (4.2)
1103 (17.8)

2314 (37.4)
2802 (45.3)
1420 (22.9)
209 (3.4)
1046 (16.9)

2
2
1
4
2

1530 (24.1)
NR
NR

8291 (19.1)
5584 (12.9)
702 (1.6)

12
7
5

1480 (23.9)
948 (15.3)
144 (2.3)

1465 (23.7)
929 (15.0)
135 (2.2)

1
1
1

NR
NR
NR

636 (1.5)
5204 (12.0)

10
17

172 (2.8)
1077 (17.4)

175 (2.8)
1004 (16.2)

0
3

270 (0.6)

6

77 (1.2)

79 (1.3)

0

1754 (27.6)
1482 (23.4)
NR
NR
NR
NR
NR
NR
NR
NR
NR

13190 (30.4)
11867 (27.3)
3128 (7.2)
2967 (6.8)
1108 (2.6)
262 (0.6)
3143 (7.2)
1583 (3.6)
1651 (3.8)
2883 (6.6)
1174 (2.7)

6
9
11
2
0
1
8
1
8
3
2

1724 (27.9)
1448 (23.4)
626 (10.1)
456 (7.4)
156 (2.5)
42 (0.7)
587 (9.5)
242 (3.9)
337 (5.4)
369 (6.0)
145 (2.3)

1679 (27.1)
1445 (23.4)
629 (10.2)
469 (7.6)
154 (2.5)
41 (0.7)
579 (9.4)
250 (4.0)
327 (5.3)
382 (6.2)
158 (2.6)

2
0
0
1
0
0
0
1
1
1
1
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12
13
ED and hospital activity
Standardized number of
ED registrations
in the last 12ht
Mean (SD)
Median (IQR)
Standardized number of
hospital admissions
in the last 24hu
Mean (SD)
Median (IQR)
Standardized number of
hospital inpatient
discharges in the last 24hv
Mean (SD)
Median (IQR)
Standardized number of ED
registrations resulting in
hospitalization, in %w
ED seasonal and time
characteristics
Time of day
0700 to <1700
1700 to <2400
0000 to <0700
Seasonx
Fall
Winter
Spring

NR
NR

271 (0.6)
195 (0.4)

1
1

34 (0.5)
22 (0.4)

48 (0.8)
27 (0.4)

4
0

1.1 (0.3)
1.1 (0.9-1.3)

1.1 (0.3)
1.0 (0.8-1.3)

20

1.1 (0.3)
1.1 (0.9-1.3)

1.1 (0.3)
1.1 (0.9-1.3)

0

1.1 (0.3)
1.1 (0.8-1.3)

1.1 (0.3)
1.1 (0.8-1.2)

3

1.1 (0.3)
1.1 (0.8-1.3)

1.1 (0.3)
1.1 (0.8-1.3)

3

1.1 (0.4)
1.1 (0.8-1.2)
47.0

1.1 (0.3)
1.1 (0.8-1.3)
49.0

3

1.1 (0.4)
1.1 (0.8-1.2)
47.1

0

4

1.1 (0.3)
1.1 (0.8-1.2)
47.3

3320 (52.3)
2226 (35.1)
800 (12.6)

24996 (57.6)
12086 (27.8)
6340 (14.6)

11
16
4

3241 (52.4)
2166 (35.0)
781 (12.6)

3314 (53.6)
2060 (33.3)
814 (13.2)

2
4
2

1502 (23.7)
1446 (22.8)
1635 (25.8)

11053 (25.5)
9991 (23.0)
11008 (25.4)

4
1
1

1475 (23.8)
1412 (22.8)
1585 (25.6)

1469 (23.7)
1421 (23.0)
1545 (25.0)

0
0
1

0
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Summer
ED physician training
Emergency Medicine
Family Medicine
Other
ED patient acuity and wait
times
CTASy
1 and 2
3
4 and 5
Time (hours) waiting for
physician assessment, mean
(SD)
CTAS 1 and 2
CTAS 3
CTAS 4 and 5
90% percentile ED length of
stay, in hours
CTAS 1 and 2
CTAS 3
CTAS 4 and 5

1763 (27.8)

11370 (26.2)

4

1716 (27.7)

1753 (28.3)

1

4642 (73.1)
1338 (21.1)
NR

33336 (76.8)
7563 (17.4)
2523 (5.7)

8
9
0

4542 (73.4)
1289 (20.8)
357 (5.8)

4541 (73.4)
1304 (21.1)
343 (5.5)

0
1
1

1321 (20.8)
3797 (59.8)
1228 (19.4)

9072 (20.9)
25241 (58.1)
9108 (21.0)

0
3
4

1294 (20.9)
3693 (59.7)
1201 (19.4)

1290 (20.8)
3736 (60.4)
1162 (18.8)

0
1
2

0.6 (0.8)
1.3 (1.3)
1.6 (1.4)

0.6 (0.9)
1.4 (1.3)
1.8 (1.6)

6
5
14

0.6 (0.8)
1.3 (1.3)
1.6 (1.4)

0.6 (0.8)
1.3 (1.2)
1.6 (1.4)

1
2
4

9
8
8

8
8
8

9
9
8

8
8
8

Abbreviations: ACR, albumin-to-creatinine ratio; AKI, acute kidney injury; CKD, chronic kidney disease; CT, computed tomography; CTAS, Canadian Triage Acuity Scale; ED,
emergency department; eGFR, estimated glomerular filtration rate; IQR, interquartile range; NR, not reported; SCr, serum creatinine; SD, standard deviation; SNRI, serotoninnorepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
To convert SCr from SI units (µmol/L) to traditional units (mg/dL), divide by 88.42.
a
Data reported as n (%) unless otherwise noted. To comply with privacy regulations for minimizing the chance of patient re-identification, numbers of patients were suppressed in
the case of five or fewer patients. The total number of patients was not reported if there were other calculations that could result in the re-identification of five or fewer patients.
b
Pharmacy forward sortation area refers to a region in Ontario represented by the first three letters of the postal code. This variable describes the number and proportion of
individuals who live in the same region as the pharmacy that provided them with prescription medications.
c
Look-back window for co-morbidities was five years unless otherwise noted.
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d

Does not include angina.
Major cancers include the following tissues/organs: lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovaries, and esophagus.
f
Look-back window for the Charlson co-morbidity index was two years.63,64
g
The Aggregated Diagnosis Groups (ADG) point score, derived from the John Hopkins Adjusted Clinical Groups® system, score is a weighted measure of health care utilization
as a proxy measure for co-morbidity and accounts for the duration of condition, severity of condition, diagnostic certainty, etiology of the condition, and specialty care
involvement.65,66 The higher ADG score, the greater the co-morbidity. Individuals with an ADG score of 0 to 2 reflect low health care costs with no prior hospitalizations; ADG
score 3 to 5, high health care costs but no prior hospitalizations; ADG score 6 or more, high health care costs and at least one prior hospitalization.
h
Look-back window for medication utilization was 120 days.
i
Patients in long-term care were identified from the Ontario Drug Benefit (ODB) database.
j
Percentages reported are based on the number of ODB program eligible patients (age 65 years and older).
k
Does not includes acetylsalicylic acid.
l
Pre-ED look-back window was 7 to 365 days.
m
CKD risk categories derived from the 2012 Kidney Diseases: Improving Global Outcomes consensus guidelines. In addition to using urine ACR measurements, urine dipstick
and protein values were converted to an estimate urine ACR.67
n
Standardized difference was 9.6%.
o
Look-back window for health care utilization was 365 days unless otherwise noted.
p
Standardized difference was 10.1%.
q
Not specific for the assessment of the kidneys.
r
Urological procedures included extracorporeal shockwave lithotripsy, percutaneous nephrolithotomy, or ureteroscopic lithotripsy with stone removal.
s
For privacy considerations, individual hospital institutions were not identified.
t
Standardized to the mean number of ED registrations that occurred in the last 12-hour period over the last 14 days.
u
Standardized to the mean number of hospital admissions that occurred in the last 24-hour period over the last 14 days.
v
Standardized to the mean number of hospital discharges that occurred in the last 24-hour period over the last 14 days.
w
Proportion of registrations resulting in hospitalization standardized to each ED/hospital institution’s number of ED registrations occurring in the last 24 hours.
x
Fall: September 21 to December 20; Winter: December 21 to March 20; Spring: March 21 to June 20; Summer: June 21 to September 20.
y
Patients with a CTAS of 1 or 2 need to be seen immediately 98% of the time or within 15 minutes 95% of the time, respectively. Patients with a CTAS of 3 or 4 need to be seen
within 30 minutes 90% of the time or 60 minutes 85% of the time, respectively. Patients with a CTAS of 5 need to be seen within 120 minutes 80% of the time.
e
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Table 5-7: Thirty-Day Risk of All-Cause Mortality and Need for Hospital-Based Acute
Dialysis in a Matched Cohort of Patients in the Discharged Subpopulation

Outcome
All-cause mortality
Receipt of hospitalbased acute dialysis

ED patient events, n (%)
Discharged
Discharged
home with
home with
AKI
no AKI
(N = 6188)
(N = 6188)
136 (2.2)
87 (1.4)
19 (0.3)

7 (0.1)

Relative riska
(95% CI)

P value

1.56 (1.20-2.04)

0.001

2.71 (1.22-6.02)

0.014

Abbreviations: AKI, acute kidney injury; CI, confidence interval; ED, emergency department.
a
Patients discharged home from the ED with no AKI served as the referent group.
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Table 5-8: The Association Between Acute Kidney Injury and 30-Day All-Cause
Mortality in the Discharged Subpopulation Examined in a Subgroup Defined by PreEmergency Department Chronic Kidney Disease Stage

Pre-ED CKD stagea
eGFR≥60
45≤eGFR<60
30≤eGFR<45
eGFR<30d

ED patient events, n/N (%)b
Discharged
Discharged
home with
home with
AKI
no AKI
67/3904 (1.7) 47/3904 (1.2)
34/1054 (3.2) 16/1054 (1.5)
16/803 (2.0) 13/803 (1.6)
19/427 (4.4) 11/427 (2.6)

Relative riskc
(95% CI)

Interaction
P value

1.43 (0.99-2.06)
2.13 (1.19-3.80)
1.23 (0.59-2.56)
1.73 (0.83-3.59)

0.57

Abbreviations: AKI, acute kidney injury; CI, confidence interval; CKD, chronic kidney disease; ED, emergency
department; eGFR, estimated glomerular filtration rate.
a
CKD stage was defined using eGFR categories, reported in mL/min/1.73m2.
b
n = number of events, N = number at risk.
c
Patients discharged home from the ED with no AKI served as the referent group.
d
Patients with an eGFR 15 to <30 were combined with patients with an eGFR <15 (but not on dialysis) to comply
with ICES privacy regulations for reporting small numbers.
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Chapter 6

6

Discussion

6.1 Summary of Findings
In this population-based cohort study of adults discharged home from the ED with AKI,
149 (2.3%) died within 30 days and this proportion increased with AKI severity.
Compared to patients who were hospitalized with AKI, patients discharged home from
the ED with AKI had a lower risk of death (3.0% vs. 11.9%) and a trend towards a lower
risk of subsequent dialysis (0.4% vs 0.8%). Although the two groups in the AKI
subpopulation had comparable characteristics, the divergence in outcomes highlights the
accuracy of ED clinicians in discerning subtle clinical differences in patients with AKI.
Sicker patients destined for worse outcomes were appropriately hospitalized.
Nonetheless, the adverse outcomes of AKI following an ED discharge are clearly
highlighted when the relative association between an ED discharge and mortality was
attenuated with more severe forms of AKI. Furthermore, patients discharged home with
AKI as compared to a similar cohort of ED patients discharged home with no AKI was
associated with a 1.6-fold increase in mortality (2.2% vs. 1.4%) and an increased need for
hospital-based acute dialysis (0.3% vs. 0.1%) within 30 days. Among the three groups
studied, an ED discharge home with AKI represents an intermediate risk population.

6.2 Interpretation of Findings
6.2.1

Mortality

The 30-day mortality risk in patients discharged home from the ED with AKI is not
insignificant when compared to studies of other ED patient populations. For example,
fewer patients died within 30 and 90 days of an ED discharge with chest pain (0.2%) and
a transient ischemic attack (2%), respectively.90,91 Without conducting a formal analysis
and accounting for differences in study methodology, the higher risk of mortality in our
cohort is likely because of a greater burden of co-morbidity. Conversely, other studies
showed that more patients died within 30 days of ED discharge with heart failure (4%) or
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unstable angina (5%).92,93 The lower risk of mortality is likely because a proportion of
AKI in our cohort may be caused by mild, reversible hemodynamic changes and
therefore may confer better short-term outcomes.
Two of the five studies we identified in our literature review examined mortality on
patients discharged home from the ED with AKI. No deaths were observed within 30
days of an ED discharge home with AKI among 31 patients.52 It is unclear whether the
risk of 30-day mortality would be similar to our study had the authors examined a larger
sample size. In the study by Holmes et al., the 90-day mortality for 2719 ED patients
with AKI not hospitalized was 10-15%.50 A similar risk of 90-day mortality was observed
by Talabani et al., although their study included patients diagnosed or managed either in
the community or hospital setting.49 Future studies in our region could examine outcomes
with a similar follow-up period.
We found that most patients had mild AKI and that mortality was far more common than
the need for hospital-based acute dialysis. In this setting, our study suggests that AKI
may be a marker of illness severity.94

6.2.1.1

Subgroup Analysis of the AKI Subpopulation

We explored AKI stage as a subgroup in the analysis of the AKI subpopulation as prior
studies demonstrated that severe forms of AKI confer worse outcomes.4,8,18–20 Our results
demonstrated comparable mortality in a matched subgroup of patients with stage 3 AKI,
where regardless of ED disposition, one in six patients with similar baseline
characteristics died within 30 days of the index date. The high risk of mortality may
reflect the progression of an underlying illness as approximately one-third of patients
inevitably required admission to hospital within the same follow-up period.

6.2.1.2

Subgroup Analysis of the Discharged Subpopulation

We explored CKD stage as a subgroup in the analysis of the discharged subpopulation.
CKD did not modify the association between AKI and short-term mortality. Prior studies
suggest there is an interaction between AKI and CKD on mortality. In one study by Han
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et al. showed that the presence of CKD exaggerated the association between AKI and the
one-year risk of mortality in patients who had coronary artery bypass graft surgery.55 In
our subgroup analysis, the effect of CKD on the association between AKI and mortality
was not apparent within 30 days of an ED visit and could have been observed with longer
follow-up periods. Another explanation is that we studied a group of patients whose
characteristics and outcomes were unknown and who differ from patients with AKI in
other clinical settings.42,43 How CKD modifies the association between AKI and mortality
in non-hospitalized patients requires further study.

6.2.2

Hospitalization and Follow-Up

The need for hospitalization within 30 days of an ED discharge with AKI occurred in
1032 (16.3%) patients. Our findings are similar to the 30-day readmission rates (15-20%)
among AKI survivors discharged after hospitalization.95–97 We also found a discrepancy
between a proportion of patients who received outpatient physician follow-up (68%) and
those who had repeat SCr measurements (23%), raising questions on whether AKI was
the main reason for the outpatient visit, physicians recognized the presence of AKI, or
appropriate measures were taken to avoid hospitalization. Our findings suggest outpatient
follow-up is inadequate, consistent with the study by Scheuermeyer et al. where only 4 of
31 patients discharged home from the ED with AKI received renal-specific follow-up.52

6.3 Study Strengths
This is the first comprehensive study to examine the characteristics and outcomes of
patients discharged home from the ED with AKI. We are not aware of any studies
describing this group since the publication of this work.47 None of the studies identified
in our literature review examined the AKI subpopulation as the primary cohort of
interest.48–52
Using a combination of administrative and laboratory databases at ICES, we were able to
obtain a large sample size and examine clinically important outcomes. With a large
number of baseline characteristics available, we were able to provide context for these
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outcomes using propensity scores and two ED referent groups. Finally, we were able to
use most current definition for the diagnosis and staging of AKI with SCr
concentrations.14 We ascertained patients who would have otherwise been missed had we
exclusively relied on diagnostic codes.41 As shown on Figure 5-1, only 56 patients
discharged home from the ED were assigned an ICD-10 code for AKI.

6.4 Limitations
6.4.1

Generalizability

Our results are generalizable to residents in Southwestern Ontario captured by our data
sources. We had access to SCr concentrations from two laboratory databases. The Cerner
electronic health record is used in 13 hospital institutions and Dynacare Medical
Laboratories represents approximately one-third of Ontario residents.60,61 We could not
obtain patients who had pre-ED visit baseline SCr measurements done in other outpatient
laboratories or hospitals in Ontario.
In the analysis of the AKI and discharged subpopulations, our results are generalizable to
patients included in the match. We could not match 1967 (31%) patients in the AKI
subpopulation and 158 (3%) patients in the discharged subpopulation using our
propensity score models. Furthermore, medication information was only available for a
subset of patients eligible for universal drug coverage. We minimized the impact of
missing medication information by balancing the co-morbidities for which these
medications are indicated.

6.4.2

Interpretation of Findings

Factors such as hemodynamic stability and the ED physician’s clinical assessment of
patient safety and appropriateness for discharge home cannot be ascertained by
administrative data. We also could not determine with certainty if ED physicians did not
recognize the AKI. For many patients, we suspect that AKI was in fact recognized,
appropriately managed, and deemed safe for discharge home.52 Further details would
require a detailed chart review best collected in a prospective fashion.
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A significant proportion of individuals discharged home from the ED with AKI required
hospitalization within 30 days. We are unable to establish if the need for hospitalization
was preventable or inevitable. Patients may have been appropriately hospitalized after
being strategically discharged from a rural ED and instructed to seek further care at a
tertiary care centre. Such patients would be considered an ED discharge.

6.4.3

Selection Bias

We excluded patients discharged home from the ED with an improvement in AKI
severity (1695 patients) and those assigned an ICD-10 code for AKI (56 patients). These
individuals may differ systematically from those who did not have an improvement in
AKI severity or were recognized by physicians with an ED main diagnosis of AKI.98 We
elected to restrict our analysis to a specific group of patients less likely to be recognized
and treated by ED physicians because we felt these patients would most likely benefit
from an intervention that combines active surveillance and increased awareness with
timely renal-specific outpatient follow-up (Chapter 6.5). Interpretation of the
characteristics and outcomes of our main cohort and two matched analyses should bear
this limitation in mind.

6.4.4

Residual Confounding

Our results are subject to confounding as propensity score matching will only ensure
balance on measured characteristics. We did not include the ED main diagnosis in our
propensity score models as the diagnosis is often preliminary and there is significant
disagreement with main diagnoses assigned at later stages of patient care.99–101 There was
also significant variability in the ED main diagnosis assigned to patients (Appendix H).
Inclusion of the ED main diagnosis would have resulted in very few matched patients.
Although the exclusion of the ED main diagnosis is a source residual confounding, we
felt it was both valuable and worthwhile to provide health care providers context for our
outcomes.
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6.5 Study Implications
6.5.1

Recommendations for Future Research

We restricted our cohort to a very specific group of patients with AKI. Additional studies
could be performed to include patients with AKI who were excluded from our main
cohort. Future data sets linked at ICES may include larger laboratory databases more
representative of all residents in Ontario. We would also be able to include new baseline
characteristics and help confirm the association between an ED discharge home with AKI
and mortality. However, there are several other knowledge gaps in this area that warrant
further attention. A prospective chart review would be required to understand why some
patients are at high risk of death or early hospitalization and to establish the reasons for a
discrepancy between the proportion of outpatient physician visits and kidney function
testing. Additional research is required to ascertain differences in patient characteristics
between those destined for adverse outcomes and poor outpatient follow-up. Finally,
future studies could examine long-term outcomes similar to those done for survivors of
AKI patients after hospitalization.22,26,28

6.5.2

Health System Strategies

There is an opportunity to explore health system strategies to improve the identification
and management of patients discharged home from the ED with AKI. Studies have
demonstrated that rapid access clinics for patients discharged home from the ED with
chest pain, heart failure, or a transient ischemic attack can improve patient outcomes.102–
104

Furthermore, AKI survivors discharged after hospitalization appear to benefit from

follow-up clinics.30 A similar model could be adapted for patients discharged home from
the ED with AKI, supported by an automated surveillance system to facilitate AKI
identification and increased awareness by all health care providers.105 AKI surveillance
systems have become increasingly popular in the United Kingdom and could serve as a
model for design and implementation to improve the process of care for patients in our
region.50
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6.6 Conclusion
Patients with moderate-to-severe AKI at significant risk of 30-day adverse outcomes such
as all-cause mortality and subsequent hospitalization. Compared to a hospital admission
with AKI and an ED discharge with no AKI, patients discharged home from the ED with
AKI are an intermediate risk population. Additional research into risk factors for adverse
outcomes, further characterization of ED and outpatient care, and testing health system
strategies to identify and mitigate gaps in care appears warranted.
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Appendices
Appendix A: MEDLINE/Ovid Search Strategy to Identify Studies Describing Patients
Discharged Home from the Emergency Department with Acute Kidney Injury.
#
1b

MEDLINE/Ovid search
Resultsa
((acute adj2 (kidney or renal or nephr$ or glomer$ or h?emodialy$ or
257042
dialysis)).mp OR exp Acute Kidney Injury/ OR ((kidney or renal) adj
injur$).tw OR exp Kidney Diseases/ci OR (tubul$ adj (injury or
necrosis or damage)).tw OR nephrotox$.tw OR Nephritis, Interstitial/
OR ((tubulointerstitial or interstitial) adj nephr$).tw OR ((kidney$ or
renal) adj isch?emi$).tw OR (induced adj (kidney or renal)).tw OR (h?
emolytic ur?emi$).tw OR *Hemolytic-Uremic Syndrome/ OR aki.tw
OR oliguri$. mp or anuri$.mp OR anti-glomerular.mp OR
antiglomerular.mp OR Kidney Cortex Necrosis/ OR pre-renal.tw or
prerenal.tw OR anti-gbm.tw OR (obstruct$ adj2 (kidney$ or
nephropath$ or renal or uropathy)).tw OR hepatorenal syndrome. mp
OR *Hemorrhagic Fever with Renal Syndrome/ OR (thrombotic adj
(thrombocytopeni$ or microangiopathy)).tw OR exp Acidosis/ci OR
renal hypoperfusion.tw OR (worsening and renal).tw OR ((improved
or recover$ or impair$) adj2 renal function).tw OR azot?emi$.mp OR
(renal adj2 thrombosis).tw OR ((Reperfusion Injury/ OR
(isch?emi$ adj (reperfusion or injury)).tw OR (critical$ adj (care or
ill$ or patient$)).mp OR sepsis.mp OR septic.mp OR intensive care.mp
OR icu.tw OR tubular cell$.tw OR rhabdomyolysis.mp OR
thrombocytopeni$.tw OR life-threatening.mp OR vasculit$.mp OR
polyarteritis.mp OR ((multi$ organ or multiorgan) adj (failure or
dysfunction)).mp OR cardiogenic shock.tw OR Blood Urea Nitrogen/
OR polyangiitis.mp OR wegener$ granulomatosis.mp) AND
(kidney.mp OR renal.mp OR dialysis.mp OR ur?emi$.tw OR
dehydrat$.mp OR creatinin$.mp)) OR (nephropath$ AND
((contrast$ adj (medi$ OR induced OR agent$)) OR radiocontrast$ OR
iodinated OR crystal$ OR cast)).mp. OR ((glomerulonephritis.mp OR
nephrit$.tw) AND (acute.tw OR crescentic.mp OR anca$.tw OR
rapidly progressive.tw)) OR ((Kidney Diseases/ OR (renal adj
(insufficienc$ or failure or function or impairment)).mp OR ischemiareperfusion injury.tw OR glomerular filtration rate.tw) AND (exp
*Cardiovascular Surgical Procedures/ OR Cardiovascular Diseases/
OR exp *Cardiovascular System/ su OR cardiac surg$.mp OR
cardiopulmonary.tw OR Ischemia/ OR exp *diagnostic imaging/ OR
exp Neurologic Manifestations/ OR *Contrast Media/ OR
preoperative$.tw OR pre-operative$.tw OR postoperative$.tw OR
post-operative$. tw OR exp Substance-Related Disorders/ OR
microangiopath$.tw OR cirrhosis.ti OR revers$.tw OR ci.fs)) OR
((injury.mp or isch?emi$.mp or reperfusion.mp or contrast medi$.mp)
AND (renal tubul$.tw or tubular.tw)))

91

2c

3
4
5
6
7
a

Emergency Treatment/ or Emergency Medicine/ or emergency medical
services/ or emergency service, hospital/ or trauma centers/ or triage/
or exp Evidence-Based Emergency Medicine/ or exp Emergency
Nursing/ or Emergencies/ or emergicent* or casualty department* or
((emergenc* or ED) adj1 (room* or accident or ward or wards or unit
or units or department* or physician* or doctor* or nurs* or
treatment*orvisit*)).mp. or (triage or critical care or (trauma adj1
(cent* or care))).mp
(communit$ OR community OR community-acquired OR community
acquired OR outpatien$ OR ambul$ OR ambul$ care OR primar$ care)
1 and 2
1 and 3
4 or 5
Limit 6 to English language

Results are up to date as of August 10, 2017 and excludes the citation related to this thesis.47
Search filters for acute kidney injury are described by Hildebrand et al.45
c
Search filters for emergency department studies are described by Campbell, S.44
b
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Appendix B: Checklist of Recommendations for Reporting of Observational Studies Using the STrengthening the Reporting of
OBservational Studies in Epidemiology (STROBE) Guidelines
Section
Title and
abstract

Item no.
1a
1b

Introduction
Background

2

Objectives

3

Methods
Study design
Setting

4
5

Participants

6

Variables

7

Data sources and
measurement

8

Bias
Study size
Quantitative
Variables
Statistical methods

9
10
11
12a
12b
12c
12d

Recommendation
Indicate the study’s design with a commonly used term in the title or the abstract
Provide in the abstract an informative and balanced summary of what was done
and what was found
Explain the scientific background and rationale for the investigation being
reported
State specific objectives, including any prespecified hypotheses
Present key elements of study design early in the paper
Describe the setting, locations, and relevant dates, including periods of
recruitment, exposure, follow-up, and data collection
Give the eligibility criteria, and the sources and methods of selection of
participants. Describe methods of follow-up.
Clearly define all outcomes, exposures, predictors, potential confounders, and
effect modifiers. Give diagnostic criteria, if applicable
For each variable of interest, give sources of data and details of methods of
assessment (measurement). Describe comparability of assessment methods if
there is more than one group
Describe any efforts to address potential sources of bias
Explain how the study size was arrived at
Explain how quantitative variables were handled in the analyses. If applicable,
describe which groupings were chosen and why
Describe all statistical methods, including those used to control for confounding
Describe any methods used to examine subgroups and interactions
Explain how missing data were addressed
If applicable, explain how loss to follow-up was addressed

Reported
i
ii
Chapters 1-2
Chapter 3
Chapter 4
Chapter 4
Chapter 4
Chapter 4
Chapter 4
Chapter 4
Chapter 4
Chapter 4
Chapter 4
Chapter 4
Chapter 4
Not applicable
92

12e

Describe any sensitivity analyses

Results
Participants

13a

Chapter 5

Descriptive data

13b
13c
14a

Outcome data
Main results

14b
14c
15
16

Report numbers of individuals at each stage of study—e.g. numbers potentially
eligible, examined for eligibility, confirmed eligible, included in the study,
completing follow-up, and analysed
Give reasons for non-participation at each stage
Consider use of a flow diagram
Give characteristics of study participants (e.g. demographic, clinical, social) and
information on exposures and potential confounders
Indicate number of participants with missing data for each variable of interest
Summarise follow-up time (e.g., average and total amount)
Report numbers of outcome events or summary measures over time
Give unadjusted estimates and, if applicable, confounder-adjusted estimates and
their precision (e.g., 95% confidence interval). Make clear which confounders
were adjusted for and why they were included
Report category boundaries when continuous variables were categorized
If relevant, consider translating estimates of relative risk into absolute risk for a
meaningful time period
Report other analyses done—e.g. analyses of subgroups and interactions, and
sensitivity analyses
Summarise key results with reference to study objectives
Discuss limitations of the study, taking into account sources of potential bias or
imprecision. Discuss both direction and magnitude of any potential bias.
Give a cautious overall interpretation of results considering objectives,
limitations, multiplicity of analyses, results from similar studies, and other
relevant evidence
Discuss the generalizability (external validity) of the study results

Chapter 6
Chapter 6

Other analyses

17

Discussion
Key results
Limitations

18
19

Interpretation

20

Generalizability

21

Not applicable

Chapter 5
Chapter 5
Chapter 5
Chapter 5
Chapter 5
Chapter 5
Chapter 5

Chapter 5
Chapter 5
Chapter 5

Chapter 6
Chapter 6

Other information
93

Funding

22

Give the source of funding and the role of the funders for the present study and,
if applicable, for the original study on which the present article is based

Acknowlegements
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Appendix C: Coding Definitions for Co-Morbid Conditions
Variable
Abdominal aortic
aneurysm repair
Atrial fibrillation or
flutter
Major cancera

Database
CIHI-DAD
OHIP
CIHI-DAD
CIHI-DAD

Code set
CCP
CCI
Fee code
ICD-9
ICD-10
ICD-9
ICD-10

Chronic liver disease

OHIP
CIHI-DAD

Diagnosis
ICD-9
ICD-10

OHIP
Chronic obstructive
pulmonary disease
Coronary artery
disease (excluding
angina)

CIHI-DAD
CIHI-DAD

OHIP
Dementia

CIHI-DAD

Diagnosis
Fee code
ICD-9
ICD-10
CCP
CCI
ICD-9
ICD-10
Diagnosis
Fee code
ICD-9
ICD-10

Code
5024, 5034
1KA76
R802, R816, R817, R783, R784, R785, R814
4273
I48
150, 154, 155, 157, 162, 174, 175, 185, 203, 204, 205, 206, 207, 208, 2303,
2304, 2307, 2330, 2312, 2334
971, 980, 982, 984, 985, 986, 987, 988, 989, 990, 991, 993, C15, C18, C19,
C20, C22, C25, C34, C50, C56, C61, C82, C83, C85, C91, C92, C93, C94,
C95, D00, D010, D011, D012, D022, D075, D05
203, 204, 205, 206, 207, 208, 150, 154, 155, 157, 162, 174, 175, 183, 185
4561, 4562, 070, 5722, 5723, 5724, 5728, 573, 7824, V026, 571, 2750, 2751,
7891, 7895
B16, B17, B18, B19, I85, R17, R18, R160, R162, B942, Z225, E831, E830,
K70, K713, K714, K715, K717, K721, K729, K73, K74, K753, K754, K758,
K759, K76, K77
571, 573, 070
Z551, Z554
491, 492, 496
J41, J43, J44
4801, 4802, 4803, 4804, 4805, 481, 482, 483
1IJ50, 1IJ76
412, 410, 411
I21, I22, Z955, T822
410, 412
R741, R742, R743, G298, E646, E651, E652, E654, E655, Z434, Z448
2900, 2901, 2903, 2904, 2908, 2909, 2948, 2949, 3310, 3311, 3312, 2941, 797
F065, F066, F068, F069, F09, F00, F01, F02, F03, F051, G30, G31, R54
95

b

Diabetes

OHIP
CIHI-DAD
OHIP

Heart failure

CIHI-DAD

OHIP
Hypertensionb

CIHI-DAD

Nephrolithiasis

OHIP
CIHI-DAD

Osteoarthritis

CIHI-DAD

Parkinson’s disease

CIHI-DAD

Peripheral vascular
disease

CIHI-DAD

Rheumatoid arthritis

Diagnosis
ICD-9
ICD-10
Diagnosis
Fee code
ICD-9
ICD-10
CCP
CCI
Diagnosis
Fee code
ICD-9
ICD-10
Diagnosis
ICD-9
ICD-10
ICD-9
ICD-10
ICD-9
ICD-10
ICD-9
ICD-10
CCP
CCI

OHIP

Fee code

CIHI-DAD

ICD-9
ICD-10
Diagnosis

OHIP

290, 331, 797
250
E10, E11, E13, E14
250
Q040, K029, K030, K045, K046
425, 5184, 428, 514
I500, I501, I509, I255, J81
4961, 4962, 4963, 4964
1HP53, 1HP55, 1HZ53GRFR, 1HZ53LAFR, 1HZ53SYFR
428
R701, R702, Z429
401, 402, 403, 404, 405
I10, I11, I12, I13, I15
401, 402, 403
5920, 5921, 5929, 5940, 5941, 5942, 5948, 5949, 27411
N200, N201, N202, N209, N210, N211, N218, N219, N220, N228
715
M15, M16, M17, M18, M19, M47
332
G20, F023
4402, 4408, 4409, 5571, 4439, 444
I700, I702, I708, I709, I731, I738, I739, K551
5125, 5129, 5014, 5016, 5018, 5028, 5038, 5126, 5159
1KA76, 1KA50, 1KE76, 1KG50, 1KG57, 1KG76MI, 1KG87, 1IA87LA,
1IB87LA, 1IC87LA, 1ID87LA, 1KA87LA, 1KE57
R787, R780, R797, R804, R809, R875, R815, R936, R783, R784, R785, E626,
R814, R786, R937, R860, R861, R855, R856, R933, R934, R791, E672, R794,
R813, R867, E649
714
M05, M06
714
96

Cerebrovascular
diseasec

CIHI-DAD

ICD-9
ICD-10

430, 431, 432, 4340, 4341, 4349, 435, 436, 3623
I62, I630, I631, I632, I633, I634, I635, I638, I639, I64, H341, I600, I601, I602,
I603, I604, I605, I606, I607, I609, I61, G450, G451, G452, G453, G458, G459,
H340

Abbreviations: CCI, Canadian Classification of Health Interventions; CCP, Canadian Classification of Diagnostic, Therapeutic and Surgical Procedures; CIHI-DAD, Canadian
Institute for Health Information Discharge Abstract Database; ICD-9, International Classification of Diseases, Ninth Revision; ICD-10, International Classification of Diseases,
Tenth Revision; OHIP, Ontario Health Insurance Plan.
a
List of major cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovarian, and esophageal cancers.
b
Oral hypoglycemic medications and insulin were not considered as not all patients have medication information available.
c
Cerebrovascular disease: stroke or transient ischemic attack.
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Appendix D: Diagnostic Codes for Health Care Utilization Characteristics
Variable
Family physician
visit

Database
OHIP

Code set
Fee code

IPDB

Main
specialty
Fee code
Main
specialty
Fee code

Internal medicine
physician visit

OHIP
IPDB

Nephrologist visit

OHIP
IPDB

Urologist visit

OHIP
IPDB

Coronary
angiogram or
revascularization
CT scan with
contrast

CIHI-DAD

Echocardiogram

CIHI-DAD

OHIP
CIHI-DAD

Main
specialty
Fee code
Main
specialty
CCP
CCI
Fee code
CCI

CCP
CCI

Code
A001, A003, A004, A005, A006, A007, A008, A900, A901, A905, A911,
A912, A967, K131, K132, K140, K141, K142, K143, K144, W003, W008,
W121
GP/FP
A135, C135
INTERNAL MEDICINE
A135, A161, A163, A164, A165, A166, A168, C101, C138, G860, G323,
G333, E083, C132, C135, C137, C139, H540, G325, G326, G860, G865,
G866, G330, G331, G332, G861, G864
NEPHROLOGY
A355, A356, A353, A354, C355, C356, C353, C354 Z606, Z628, Z632, Z633,
Z634, S655, S654
UROLOGY
4892, 4893, 4894, 4895, 4896, 4897, 4898, 481, 482, 483, 480
3IP10, 3IS10, 1IJ50, 1IJ26, 1IJ27, 1IJ57, 1IJ76, 1IJ57GQ, 1IJ54GQAZ
G297, G509, R741, R742, R743, E651, E652, E654, E646, G298, Z434, G262
3AF20WC, 3AN20WC, 3CA20WC, 3DR20WC, 3EA20WC, 3EL20WC,
3ER20WC, 3EY20WC, 3FX20WC, 3FY20WC, 3GE20WC, 3GT20WC,
3GY20WC, 3ID20WC, 3IP20WC, 3JE20WC, 3JX20WC, 3JY20WC,
3KE20WC, 3KG20WC, 3KT20WC, 3NM20WC, 3OT20WC, 3PC20WC,
3PZ20WC, 3QT20WC, 3SC20WC, 3SF20WC, 3TZ20WC, 3VZ20WC,
3WZ20WC, 3YM20WC, 3ZZ20WC, 3FY20VZ, 3FY20VC
0282
3IP30
98

Cardiac stress test

Abdominal
ultrasoundb
Kidney stone
interventionsc

OHIP

Fee codea

CIHI-DAD
OHIP

CCP
CCI
Fee code

OHIP

Fee code

G560, G561, G562, G566, G567, G568, G570, G571, G572, G574, G575,
G576, G577, G578, G581
0341, 0342, 0343, 0344, 0605
2HZ08, 3IP70
G315, G174, G111, G112, G319, G582, G583, G584, J607, J608, J807, J808,
J809, J866, J609, J666
J128, J135, J428, J435

OHIP

Fee code

Z630, Z628, E760, E761, Z624, Z627

CCI, Canadian Classification of Health Interventions; CCP, Canadian Classification of Diagnostic, Therapeutic and Surgical Procedures; CIHI-DAD, Canadian Institute for Health
Information Discharge Abstract Database; CT, computed tomography; OHIP, Ontario Health Insurance Plan.
a
G560, G561, G562, G566, G567, G568, G576 are no longer in fee schedule as of 2014/11.
b
An abdominal ultrasound is not specific to the kidneys.
c
Urological procedures included extracorporeal shockwave lithotripsy, percutaneous nephrolithotomy, or ureteroscopic lithotripsy with stone removal.
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Appendix E: Diagnostic Codes for Exclusion Criteria
Variable
Dialysis

Database
CIHI-DAD

Code set
ICD-9
ICD-10
CCP
CCI

OHIP

Fee code

Kidney
transplant
Palliative care

CIHI-DAD
OHIP
CIHI-DAD
OHIP

CCI
Fee code
PATSERV
Fee code

AKI

CIHI-DAD/
NACRS

ICD-10

Code
V451, V560, V568, 99673
T824, Y602, Y612, Y622, Y841, Z49, Z992
5127, 5142, 5143, 5195, 6698
1PZ21, 1OT53DATS, 1OT53HATS, 1OT53LATS, 1SY55LAFT, 7SC59QD,
1KY76, 1KG76MZXXA, 1KG76MZXXN, 1JM76NC, 1JM76NCXXN
R850, G324, G336, G327, G862, G865, G099, R825, R826, R827, R833,
R840, R841, R843, R848, R851, R946, R943, R944, R945, R941, R942,
Z450, Z451, Z452, G864, R852, R853, R854, R885, G333, H540, H740,
R849, G323, G325, G326, G860, G863, G866, G330, G331, G332, G861,
G082, G083, G085, G090, G091, G092, G093, G094, G095, G096, G294,
G295
1PC85
S435, S434
58
C945, C882, C982, W872, W972, B966, B998, B997, G511, W882, W982,
K023 (inpatient or LTC use only)
N17

Abbreviations: AKI; acute kidney injury; CCI, Canadian Classification of Health Interventions; CCP, Canadian Classification of Diagnostic, Therapeutic and Surgical Procedures;
CIHI-DAD, Canadian Institute for Health Information Discharge Abstract Database; ICD-9, International Classification of Diseases, Ninth Revision; ICD-10, International
Classification of Diseases, Tenth Revision; NACRS, National Ambulatory Care Reporting System; OHIP, Ontario Health Insurance Plan; PATSERV, patient service.
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Appendix F: Diagnostic Codes for Outcome Variables
Variable
Mortality
Receipt of hospital-based acute
dialysis
Health care cost

Outpatient physician visit by
any one of:
Family physician
General internist
Nephrologist
Urologist

Database
RPDB
OHIP

Code set
Vital status
Fee code

ADP, CAPE, CCRS,
CIHI-DAD/NACRS,
HCD, NRS, ODB,
OHIP, OMHRS
OHIP

Code
Vital status field
R849, G323, G866, G330, G331, G093, G095, G294,
G2955 associated with hospital admission
ICES costing macro62

Fee code

GP/FP: A001, A003, A004, A005, A006, A007, A008,
A900, A901, A905, A911, A912, A967, K131, K132,
K140, K141, K142, K143, K144, W003, W008, W121
Internal Medicine: A135, C135
Nephrology: A135, A161, A163, A164, A165, A166,
A168, C101, C138, G860, G323, G333, E083, C132,
C135, C137, C139, H540, G325, G326, G860, G865,
G866, G330, G331, G332, G861, G864
Urology: A355, A356, A353, A354, C355, C356, C353,
C354 Z606, Z628, Z632, Z633, Z634, S655, S654
GP/FP, INTERNAL MEDICINE, NEPHROLOGY,
UROLOGY
067A
Test done=”A”
L067
05DR, 05DU, P/CR, P/CM, 208Y, 208Z, 253

IPDB
SCr measurement
Urine protein measurement
(dipstick, ACR, or PCR)

Dynacare
Cerner
OHIP
Dynacare
OHIP

Main
specialty
Fee code
Fee code

L253, L254, L255, L633, L634, L641, G009, G010

Abbreviations: ACR, albumin-to-creatinine ratio; ADP, Assistive Devices Program; CAPE, Client Agency Program Enrolment; CCRS, Continuing Care Reporting System; CIHIDAD, Canadian Institute for Health Information Discharge Abstract Database; GP/FP, general practitioner/family physician; HCD, Home Care Database; ICES, Institute for
Clinical Evaluative Sciences; IPDB, ICES Physician Database; NACRS, National Ambulatory Care Reporting System; NRS, National Rehabilitation Reporting System; ODB,
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Ontario Drug Benefit; OHIP, Ontario Health Insurance Plan; OMHRS, Ontario Mental Health Reporting System; PCR, protein-to-creatinine ratio; RPDB, Ontario’s Registered
Persons Database; SCr, serum creatinine.
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Appendix G: Characteristics Used to Derive Propensity Scores for the AKI Subpopulation and Discharged Subpopulation
Category

Variable

Demographics

Age, sex, income quintile, year of cohort entry, rural location, long-term care status, Pharmacy
forward sortation area
Abdominal aortic aneurysm repair, atrial fibrillation/flutter, cerebrovascular disease, chronic
liver disease, chronic obstructive pulmonary disease, coronary artery disease, dementia,
diabetes, heart failure, hypertension, major cancer, nephrolithiasis, osteoarthritis, Parkinson’s
disease, peripheral vascular disease, rheumatoid arthritis,
Charlson co-morbidity index, Aggregated Diagnosis Group point score

Co-morbid
conditions
Co-morbidity
indices
Laboratory
characteristics
Health care
utilization
Medication
characteristics
and classesd

Pre-ED visit baseline SCrb, number of days pre-ED visit baseline SCr was measuredb, pre-ED
visit baseline SCr ≤50 µmol/L, SCr value at ED visitb, urine ACR, serum potassiumb, serum
sodiumb, AKI stage, eGFR category
Prior hospitalizations, prior ED visits, family physician visit, general internist visit,
nephrologist visit, urologist visit, coronary angiogram or revascularization, CT scan with
contrast, echocardiogram, cardiac stress test, abdominal ultrasound, intervention for kidney
stones
ODB program eligibility, number of unique drug identification numbers, number of unique
drug names
Angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, alpha-1adrenoceptor antagonist or 5-alpha-reductase inhibitor, antibacterial, anticoagulant,
antidepressant (SSRI or SNRI), antineoplastic, antiplatelet, antipsychotic medication, betaadrenergic antagonist, calcium channel blocker, corticosteroid, xanthine oxidase inhibitor or
uricosuric agent, anti-retroviral medication, immunosuppressive medication, lithium, nonpotassium sparing diuretic, non-steroidal anti-inflammatory drug, oral hypoglycemic agent or
insulin, potassium-sparing diuretic, , proton pump inhibitor, statin

Number of
variablesa
7
16

2
9
12

24
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ED and hospital
characteristics

Institution (1-13)c, ED registrations in last 12 hoursb, hospital admissions in last 24 hoursb,
hospital discharges in last 24 hoursb, proportion of ED registrations admitted to hospital, ED
length of stayb, time waiting for physician assessmentb, Canadian Triage Acuity Scale, time of
day, season of the year, ED physician specialty training.
Total

23

93

Abbreviations: ACR, albumin-to-creatinine ratio; AKI, acute kidney injury; CT, computed tomography; ED, emergency department; eGFR, estimated glomerular filtration rate;
ODB, Ontario Drug Benefit; SCr, serum creatinine; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor.
a
We considered 93 variables to derive propensity scores for the AKI and discharged subpopulations. In the AKI subpopulation (comparing patients discharged home from the ED
with AKI versus patients admitted to hospital with AKI), 92 variables were used to derive the propensity score. The ED length of stay variable was not included because
admitted patients may remain in the ED until an inpatient bed is available, inflating the ED length of stay (defined as time of registration to time patient physically left the ED).
In the discharged subpopulation (comparing patients discharged home from the ED with AKI versus patients discharged home from the ED with no AKI), 91 variables were
used to derive the propensity score. ED visit SCr and AKI stage were not included in the model.
b
Continuous variables used to derive propensity scores for both the AKI and discharged subpopulation.
c
Each hospital institution (13 total) was included to derive propensity scores for both the AKI and discharged subpopulation. For privacy considerations, individual hospital
institutions were not identified.
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Appendix H: Most Common Main Diagnoses Assigned by Physicians to a Cohort of
6346 Patients Discharged Home from the Emergency Department with Acute Kidney
Injury
No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

ICD-10
R07
R10
N23
N39
R55
J18
R53
K52
E86
I48
R06
R42
N20
I50
R11
I20
L03
A09

19
20

J44
R00

Description
Pain in throat and chest
Abdominal and pelvic pain
Unspecified renal colic
Other disorders of urinary system
Syncope and collapse
Pneumonia, organism unspecified
Malaise and fatigue
Other noninfective gastroenteritis and colitis
Volume depletion
Atrial fibrillation and flutter
Abnormalities of breathing
Dizziness and giddiness
Calculus of kidney and ureter
Heart failure
Nausea and vomiting
Angina pectoris
Cellulitis
Diarrhoea and gastroenteritis of presumed infectious
origin
Other chronic obstructive pulmonary disease
Abnormalities of heart beat

Abbreviation: ICD, International Classification of Diseases.

n (%)
515 (8.1%)
447 (7.0%)
309 (4.9%)
248 (3.9%)
219 (3.5%)
175 (2.8%)
159 (2.5%)
150 (2.4%)
128 (2.0%)
123 (1.9%)
116 (1.8%)
116 (1.8%)
111 (1.7%)
110 (1.7%)
98 (1.5%)
89 (1.4%)
88 (1.4%)
77 (1.2%)
77 (1.2%)
76 (1.2%)
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